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Neuropeptides are auxiliary messenger molecules that always co-exist in nerve cells
with one or more small molecule (classic) neurotransmitters. Neuropeptides act both as
transmitters and trophic factors, and play a role particularly when the nervous system
is challenged, as by injury, pain or stress. Here neuropeptides and coexistence in
mammals are reviewed, but with special focus on the 29/30 amino acid galanin and
its three receptors GalR1, -R2 and -R3. In particular, galanin’s role as a co-transmitter
in both rodent and human noradrenergic locus coeruleus (LC) neurons is addressed.
Extensive experimental animal data strongly suggest a role for the galanin system in
depression–like behavior. The translational potential of these results was tested by
studying the galanin system in postmortem human brains, first in normal brains, and
then in a comparison of five regions of brains obtained from depressed people who
committed suicide, and from matched controls. The distribution of galanin and the four
galanin system transcripts in the normal human brain was determined, and selective and
parallel changes in levels of transcripts and DNA methylation for galanin and its three
receptors were assessed in depressed patients who committed suicide: upregulation
of transcripts, e.g., for galanin and GalR3 in LC, paralleled by a decrease in DNA
methylation, suggesting involvement of epigenetic mechanisms. It is hypothesized that,
when exposed to severe stress, the noradrenergic LC neurons fire in bursts and release
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galanin from their soma/dendrites. Galanin then acts on somato-dendritic, inhibitory
galanin autoreceptors, opening potassium channels and inhibiting firing. The purpose
of these autoreceptors is to act as a ‘brake’ to prevent overexcitation, a brake that
is also part of resilience to stress that protects against depression. Depression then
arises when the inhibition is too strong and long lasting – a maladaption, allostatic load,
leading to depletion of NA levels in the forebrain. It is suggested that disinhibition by
a galanin antagonist may have antidepressant activity by restoring forebrain NA levels.
A role of galanin in depression is also supported by a recent candidate gene study,
showing that variants in genes for galanin and its three receptors confer increased risk
of depression and anxiety in people who experienced childhood adversity or recent
negative life events. In summary, galanin, a neuropeptide coexisting in LC neurons,
may participate in the mechanism underlying resilience against a serious and common
disorder, MDD. Existing and further results may lead to an increased understanding of
how this illness develops, which in turn could provide a basis for its treatment.
Keywords: allostatic load, epigenetics, galanin, locus coeruleus, major depression disorder, neuropeptides,
resilience
INTRODUCTION
The first evidence for chemical signaling in the central nervous
system was reported by Eccles et al. (1954), when they
demonstrated that acetylcholine is the transmitter released from
motor neuron collaterals onto Renshaw cells in the spinal
cord. Some 10 years later the Canadian electrophysiologist
Hugh McLennan in his monograph “Synaptic transmission”
(McLennan, 1963) reviewed in some detail the evidence for
a number of molecules being transmitters: “Acetylcholine,”
“Catecholamines,” “5-Hydroxytryptamine,” “Substance P,” “Factor
I and the Inhibitory Transmitter,” “GABA and Glutamic Acid,”
and “Cerebellar Excitatory Factor” were the chapter sub-headings.
Some further compounds were mentioned, like other amino acids.
A detailed table of the regional distribution of these molecules
was included. In the “Conclusions” McLennan stated “With the
exception of a number of cholinergic and rather fewer adrenergic
systems, the data supporting a certain type of chemical mediation
in any given situation are quite inadequate, and in spite of the
inherent difficulties the number of problems to be solved are
of great interest.” Indeed, many efforts in the following years
rapidly expanded the number of candidates and ‘certified’ their
transmitter status – work still ongoing. However, to identify
a molecule as a transmitter was at that time often a difficult
process with strong pro and contra arguments. More recently
completely different molecules have appeared on the scene, not
stored in vesicles and thus not exocytosed, like nitric oxide (NO)
and hydrogen sulfide (H2S), sometimes called “gasotransmitters”
(Paul and Snyder, 2015). Subsequently, substance P, mentioned
already by McLennan, was identified as a member of the by far
most diverse group of signaling molecules (>100) in the nervous
system, the neuropeptides (Burbach, 2010).
The purpose of the present article is to review data on one
of these peptides, galanin, which was discovered by Tatemoto
et al. (1983) at Karolinska Institutet, a peptide that is a co-
transmitter in many systems. In particular, focus is on recent
results describing the distribution of galanin and it three
receptors GalR1-3 in the ‘normal’ human brain by studying post
mortem tissue samples (Le Maitre et al., 2013). More importantly,
results are discussed showing significant changes in expression
of the galanin family ‘members’ in post mortem brains from
depressed patients having committed suicide, as compared to
controls (Barde et al., 2016). A hypothesis is presented on a
possible role of galanin, coexisting in noradrenergic neurons
in the locus coeruleus (LC), in the development of depression
and in resilience. This hypothesis is based on results from
extensive animal experiments, so discussion of the human studies
is preceded by an overview of “neuropeptides” with some
comments on “methodological approaches,” of “neuropeptide –
small transmitter molecule coexistence,” of the neuropeptide
“galanin,” followed by a summary of the critical and relevant
animal experiments.
NEUROPEPTIDES
The concept of neuropeptide transmitters was introduced by
the late Dutch scientist David de Wied and colls. (see De
Wied and De Kloet, 1987). Neuropeptides are different from
classic transmitters in several ways (Strand, 1991). In brief,
neuropeptides are ribosomally synthesized as large precursor
molecules in cell soma and dendrites (Noda et al., 1982; Mains
et al., 1987), and the bioactive peptide(s) is excised from
prepropeptide precursors by convertase enzymes (Seidah and
Chretien, 1999). Packed in storage vesicles the peptides are
axonally transported and released by exocytosis from nerve
terminals, and also from dendrites and soma.
Neuropeptides in the nervous system encompass > 100
members (Burbach, 2010), almost always acting via one or
more of a correspondingly large number of 7-transmembrane,
G protein-coupled receptors (GPCRs) (>200). Much research is
ongoing in the neuropeptide field. A search on PubMed with the
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terms “neuropeptides, review” (August 1, 2018) generated 35.579
hits. However, work on neuropeptides has not been without
controversies. Already in the 1990’ies doubts were expressed
with regard to functional significance [see for example the article
entitled “Superfluous neurotransmitters” (i.e., neuropeptides) by
Bowers (1994)]. The recent statement by Sudhof (2017) still
reflects a cautious attitude: “At the forefront of early molecular
neuroscience was the identification of neuropeptide precursors
and neuropeptide receptors (Noda et al., 1982), but since then the
question of neuropeptide signaling has largely faded from view
with a few exceptions.”
However, peptides have an important and well accepted
physiological function, when they are expressed in
neurosecretory systems (Scharrer and Scharrer, 1937; Bargmann,
1949; Bargmann and Scharrer, 1951; Swaab et al., 1975;
Vandesande and Dierickx, 1975; Brownstein and Mezey,
1986; Swanson et al., 1986; Ceccatelli et al., 1989; Meister,
1993; Morris et al., 1998; Gainer et al., 2002; Landgraf and
Neumann, 2004; Jurek and Neumann, 2018), releasing their
peptides into the general circulation (e.g., vasopressin, oxytocin)
(Acher and Chauvet, 1954; Du Vigneaud, 1954), or into the
hypothalamic portal circulation [thyrotropin releasing hormone
(TRH), luteinizing releasing hormone (LHRH), somatostatin
(a.k.a. growth hormone release-inhibiting hormone, GHR-IH),
corticotropin releasing factor/hormone (CRF/CRH), and growth
hormone releasing hormone (GHRH)] (Guillemin, 1978; Schally
et al., 1978; Spiess et al., 1981, 1983; Vale et al., 1981; Brazeau
et al., 1982; Rivier et al., 1982).
It is fair to say that many of the initial, high expectations
of neuropeptides were not met. Examples are: (i) the discovery
of the first endogenous ligands met- and leu-enkephalin for the
morphine receptor (Hughes et al., 1975), present in dorsal horn
interneurons (Hokfelt et al., 1977b), was expected to lead to new
efficacious medicines for fighting pain, without the serious side
effects of morphine; and (ii) antagonists to substance P, present
in sensory neurons and the spinal dorsal horn (Lembeck, 1957;
Hokfelt et al., 1975b; Takahashi and Otsuka, 1975) and acting as a
transmitter (Otsuka et al., 1975; Henry, 1976) via NK1 receptors
(Mantyh et al., 1995), were anticipated to represent a new type of
painkiller.
These ‘failures’ have occurred in spite of considerable efforts
from academia and pharmaceutical companies. For example, a
substance P (neurokinin 1, NK1) antagonist was tested some
25 years later in the clinic but did not induce analgesia (Hill,
2000; Herbert and Holzer, 2002). However, and interestingly,
it was also reported in a placebo-controlled trial in patients
with moderate to severe major depression that the substance
P (NK1) antagonist MK-869 (Aprepitant, EMEND), has robust
antidepressant activity (Kramer et al., 1998). Moreover, the
improvement was similar to that observed (in the same study)
with the widely used antidepressant serotonin reuptake inhibitor
(SSRI) paroxetine (Paxil, Seroxat) and essentially without (the
common sexual) side effects seen with SSRIs (Kramer et al., 1998).
However, a phase 3 trial failed to reproduce the antidepressant
effects of MK-869 (Keller et al., 2006). Reasons for the failure
in the treatment of depression have recently been analyzed
(Rupniak and Kramer, 2017), and psychiatric studies of NK1
are still ongoing (e.g., Frick et al., 2016; Schank and Heilig,
2017). Neuropeptides and pharmacotherapy for depression will
be discussed further below.
There is, however, one ‘sphere’ where neuropeptides have
achieved a significant ‘status,’ and that is as markers for
specific neuron populations, in particular in cortex and
hippocampus 1, without defining their functional role. This said,
there are interesting examples, where a neuropeptide is essential
for particular mouse behaviors. For example, in the lateral
amygdaloid nucleus gastrin releasing peptide (GRP) regulates
fear via the GRP receptor (Shumyatsky et al., 2002), and the
same peptide and receptor modulate sighing in the preBötzinger
complex in the ventrolateral medulla oblongata (Li et al.,
2016). Arcuate AgRP neurons projecting to i.a. the parabrachial
nucleus (Broberger et al., 1998) represent another example. These
neurons are GABAergic and also express and release NPY, thus
a good example of peptide and small molecule co-transmission.
Alhadeff et al. (2018) have now shown that, of these three
molecules, NPY via its NPY Y1 receptor is selectively responsible
for a pain-inhibiting effect. Finally, based on a Drosophila study
(Asahina et al., 2014), Zelikowsky et al. (2018) use a battery
of the most recent methodologies to conduct a landmark study
that demonstrates a key role for the neuropeptide tachykinin
2/neurokinin B and its receptor NK3 in chronic isolation stress,
opening up for a new treatment strategy of this serious mood
disorder.
The therapeutic potential of neuropeptide signaling has
been extensively discussed based on animal experiments. These
experiments also consider a possible role of neuropeptides in
behaviors related to stress and mood regulation, and explore
their receptors as possible targets for antidepressant drug
development, a main theme of this review (Herbert, 1993;
Maubach et al., 1999; Hokfelt et al., 2003; Holmes et al., 2003;
Sajdyk et al., 2004; Nemeroff and Vale, 2005; Millan, 2006;
Steckler, 2008; Wu et al., 2011; Griebel and Holsboer, 2012;
Griebel and Holmes, 2013).
LOCALIZATION AND FUNCTION OF
NEUROPEPTIDES: METHODS
Four methods are of crucial importance for the exploration
of neuropeptides and their coexistence with small molecule
transmitters: Immunohistochemistry (IHC), radioimmunoassay
(RIA), in situ hybridization (ISH) and real-time (quantitative)
1There are many examples: interneurons in neocortex are partly defined by
(five) neuropeptides (Somogyi and Klausberger, 2005). For example, somatostatin-
positive cortical interneurons are associated with gamma-rhythms (Veit et al.,
2017), with the development of neuropathic pain (Cichon et al., 2017) and possibly
with mental illness (Hamm and Yuste, 2016); and galanin-immunoreactive
neurons in the medial preoptic area govern parental behavior (Wu et al., 2014),
and in the ventrolateral preoptic nucleus they are sleep active (Gaus et al., 2002).
However, in none of these studies is a functional role assigned to the peptide.
Neuropeptides as phenotype marker are thus similar to calcium-binding proteins
(such as parvalbumin) (Baimbridge et al., 1992; Andressen et al., 1993), which
e.g., in neocortex label subpopulations of interneurons, often in combination with
neuropeptides (e.g., Somogyi and Klausberger, 2005).
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polymerase chain reaction (qPCR).2 These methods allow
not only studies of the localization and levels of various
neuropeptides but also give a hint toward functionality.
Neuropeptides released from nerve endings have to be
replaced by ribosomal synthesis in cell soma followed by axonal
transport. Thus, replacement can take a considerable time, of
course especially in neurons with long projections, and especially
in large brains like the human brain. However, here dendritic
release is special as the distance between site of release and
site of synthesis is short and allows for rapid replacement. In
fact, dendritic release is associated with distinct features: peptide
release (see below) via exocytosis is stimulated by depolarization-
induced Ca2+ entry through voltage-gated calcium channels,
whereby the SNARE proteins in the dendrites may partly differ
from those in nerve endings (Ludwig and Leng, 2006; Kennedy
and Ehlers, 2011; Ovsepian and Dolly, 2011; van den Pol, 2012;
Ludwig et al., 2016).
Neuropeptide dynamics distinctly contrast those of classic
transmitters: the latter are enzymatically produced also at release
sites (in the nerve endings), and they have a membrane reuptake
mechanism (transporters) at both the cell and storage vesicle
membrane (Kanner, 1994; Liu and Edwards, 1997; Chen et al.,
2004; Eiden et al., 2004; Hahn and Blakely, 2007; Torres and
Amara, 2007). These transporters allow rapid replacement at
the site of release, i.e., no axonal transport is needed. Such
transporters have not been demonstrated for neuropeptides. This
said, there is evidence that galanin after intraventricular injection
can accumulate in a small number of neurons, e.g., in the
hippocampus (Jansson et al., 2000).
Monitoring peptide mRNA levels with ISH provides a
measure of activity of specific neurons. If analyzed in an
experimental paradigm, one may even associate involvement of
a peptide with a certain function. For example, an increase in
galanin transcripts in dorsal root ganglion (DRG) neurons, after
peripheral nerve injury, has been interpreted as a defense against
pain (Xu et al., 2008) and as a signal for repair (Hobson et al.,
2010).
However, reporting of mRNA levels alone always raises the
issue of translation: Can the presence of transcript really equal
2IHC is based on antibodies and allows demonstration of the cellular and
ultrastructural localization of peptide/proteins in the microscope. The method was
introduced already in the early 1940s by Coons et al. (1942) but was not applied to
the nervous system until almost 30 years later (Geffen et al., 1969). Since peptides
are rapidly transported out from the cell body after synthesis, the mitosis inhibitor
and axonal transport-blocker colchicine is often needed to visualize cell bodies
in the brain with this method (Barry et al., 1973; Ljungdahl et al., 1978). Using
RIA, also based on (actually often the same) antibodies, developed by Yalow and
Berson (1959) almost 60 years ago, concentrations/levels of peptides/proteins can
be quantified in tissues and fluids. ISH, also a histochemical technique, detects
nucleic acid sequences in tissue sections (Brahic and Haase, 1978; Gee et al., 1983).
Since transcripts (mRNAs) are detected, the signal labels cell soma (and to some
extent dendrites). The PCR method was invented by Mullis et al. (1987). A note
of concern: In addition to specificity problems, especially associated with IHC and
GPCRs, histochemical techniques often lack sensitivity to detect low-abundance
molecules. Evidence for this view is provided by single cell analysis (Eberwine
and Bartfai, 2011). This is particularly true for receptor transcripts, since these
proteins have a low turnover (in any case compared to releasable molecules like
neuropeptides). And only few receptor molecules are needed for signaling. The
present review may ‘underestimate’ the number of molecules that coexist in a
neuron and its signaling.
the presence of protein (peptide)? Many studies suggest this
to be the case in DRGs, for example. Also, the experiments
on human postmortem brains, where transcript (qPCR) and
peptide (RIA) were analyzed in the same samples (Barde et al.,
2016) support this view (see below). Ideally this issue can be
solved by double-labeling of individual cells: ISH for transcript
and IHC for neuropeptide (Grabinski et al., 2015). Contrasting
ISH it is, however, difficult to quantify peptide levels at the
microscopic level with IHC. Also, IHC requires fixed tissues,
whereas snap-frozen fresh tissue is used for ISH. Nevertheless,
these histochemical/biochemical approaches have been applied
in countless animal experimental studies to explore a possible
functional role of neuropeptides in specific neuronal populations.
NEUROPEPTIDE AND SMALL
TRANSMITTER COEXISTENCE
In the 1970’s several groups reported that a neuron may release
more than one transmitter. These findings were often considered
to violate “Dale’s principle,” a rule generally thought to state that
a neuron only produces and releases one neurotransmitter. This
was subsequently clarified as a misunderstanding (e.g., Eccles,
1986). Several of the early studies on transmitter co-existence
focused on invertebrates, and only on classic transmitters and
not neuropeptides (Kerkut et al., 1967; Brownstein et al., 1974;
Hanley et al., 1974; Cottrell, 1976). Since then the analysis of
co-transmission in this class of animals has been extremely
informative. Thanks to in-depth analyses of the comparatively
easily accessible and well-characterized systems in invertebrates
using front-line methods, detailed knowledge of the mechanisms
underlying co-transmission, and of its functional consequences
has been generated (as reviewed in, e.g., Kupfermann, 1991;
Bargmann, 1993; Nusbaum et al., 2017; Nassel, 2018). In
the present article, the focus is on transmitter coexistence in
mammalian systems.
In mammals, co-existence of noradrenaline (NA) and
serotonin (5-hydroxytryptamine, 5-HT) in the same synaptic
vesicle of sympathetic nerves in the pineal gland was reported
(Jaim-Etcheverry and Zieher, 1973); but, serotonin presumably
originated from pinealocytes and had been translocated into
the storage sites with the help of cell and vesicular membrane
transporter molecules. At that time, evidence was also presented
for a developmental transmitter “switch” from a cholinergic to
a noradrenergic transmitter phenotype in sympathetic neurons
in vitro, with some neurons temporarily expressing both
acetylcholine and noradrenaline (Furshpan et al., 1976); later
work revealed that this also occurred in vivo (Landis and Keefe,
1983). Furthermore, several groups, in particular Burnstock and
coworkers, provided evidence that ATP is a transmitter and co-
transmitter (Burnstock, 1972), at that time a controversial view
(Burnstock, 2012).
This was also the period when attention started to focus
on peptides/neuropeptides in the brain. David de Wied
and colleagues in the Netherlands studied the effects of
pituitary hormones on behavior (de Wied and Bohus, 1966).
Guillemin and Schally’s groups discovered that the hypothalamic
Frontiers in Neural Circuits | www.frontiersin.org 4 December 2018 | Volume 12 | Article 106
fncir-12-00106 December 21, 2018 Time: 15:28 # 5
Hökfelt et al. Galanin-Noradrenaline Coexistence and Major Depression
thyrotropin-releasing hormone is a tripeptide (Boler et al., 1969;
Burgus et al., 1970), and several new peptides were isolated
from the intestine and brain (Tatemoto and Mutt, 1980; Mutt,
1989). Also substance P was isolated from the intestine (von
Euler and Gaddum, 1931), but only after 40 years (!) was it
chemically identified as an undecapeptide (Chang and Leeman,
1970; Chang et al., 1971). Last but not least, a very large number
of important peptides were isolated from the skin of various
frog species by Erspamer et al. (1978). In a visionary review,
Burnstock raised the question “Do some nerve cells release more
than one transmitter?” with focus on ATP and also mentioning
neuropeptides (Burnstock, 1976).
At that time the neuropeptide somatostatin was, surprisingly,
localized to peripheral sympathetic neurons (Hokfelt et al.,
1977a) already known to signal via NA, the transmitter of
sympathetic neurons (von Euler, 1948; Hamberger and Norberg,
1963) (Figures 1A,B). Somatostatin had been discovered as an
inhibitor of growth hormone release from the anterior pituitary
(Brazeau et al., 1973; Vale et al., 1975; Guillemin, 2008). However,
it turned out that somatostatin was not only present, as expected,
in neurosecretory nerve endings in the hypothalamic median
eminence (Dubois et al., 1974; Hokfelt et al., 1974a; Pelletier
et al., 1975), but also in many other brain nuclei (Hokfelt et al.,
1974a, 1975a; Brownstein et al., 1975; Dubé et al., 1975; Elde
and Parsons, 1975). This indicated roles far beyond that of a
hypothalamic hormone controlling pituitary growth hormone
release. Then somatostatin was shown to have a depressant action
on cortical neurons (Renaud et al., 1975). So somatostatin in
noradrenergic neurons was the first example of coexistence of
a neuropeptide transmitter with a classic neurotransmitter in
mammals (Hokfelt et al., 1977a).
Other early examples of this type of coexistence were
vasoactive intestinal polypeptide with acetylcholine (Lundberg
et al., 1979), and the neuropeptide Y (NPY) with NA (Lundberg
et al., 1982). In the brain substance P was found in 5-HT
(serotonin) neurons (Chan-Palay et al., 1978; Hokfelt et al., 1978),
and cholecystokinin (CCK) in dopamine neurons (Hokfelt et al.,
1980b), followed by many more combinations.
Regarding function, it could be shown, for example, that
VIP contributes to the atropine-resistant vasodilation in exocrine
glands (Lundberg et al., 1980), that NPY interacts with NA in
sympathetic functions (Allen et al., 1982; Lundberg et al., 1982;
Ekblad et al., 1984), and that CCK affects dopamine release
(Kovacs et al., 1981; Starr, 1982), binding (Fuxe et al., 1981;
Murphy and Schuster, 1982) and behavior (Crawley et al., 1984).
In an elegant landmark study on a frog sympathetic ganglion Jan
and Jan demonstrated that cholinergic presynaptic fibers express
and release an LHRH-like peptide that is responsible for the late,
slow excitatory post-synaptic potential via ‘volume transmission’
(Jan and Jan, 1982).
Taken together, these findings suggested a new principle:
co-transmission - the release of a neuropeptide and a classic
(small molecule) transmitter from the same neuron. In fact, the
view emerged that neuropeptides always ‘co-exist’ with small
molecule transmitters. Moreover, many groups, using IHC at
the ultrastructural level, found that peptides are stored in large
dense core vesicles (LDCVs) (diameter ∼1,000 Å) (Goldsmith
and Ganong, 1975; Swaab et al., 1975; Vandesande and Dierickx,
1975; Castel and Hochman, 1976; Dube et al., 1976; Krisch,
1976; Pelletier et al., 1981; Merighi, 2002) (Figures 1C,E),
whereas monoamines like NA are present both in synaptic
vesicles (diameter∼500 Å) and LDCVs as shown with potassium
permanganate fixation (KMnO4) (Figure 1D) (Richardson, 1966;
Hokfelt and Jonsson, 1968). The number of LDCVs in a nerve
ending is mostly low compared to synaptic vesicles, indicating
a lower content of peptide molecules vs. classic transmitters.
However, the affinity at peptide receptors is in the low nanomolar
range, allowing efficacious signaling even by low numbers of
peptide molecules in the extracellular space.
It was not clear, whether IHC could exclude that peptides
are stored in synaptic vesicles. Pelletier et al. (1981) incubated
adjacent, ultrathin sections with antibodies against substance
P and 5-HT, respectively, but in both cases only LDCVs were
stained, not synaptic vesicles. This in spite of the fact that
monoamines are (mainly) stored in synaptic vesicles (Figure 1D).
Thus, it did not seem possible to visualize the main transmitter
(5-HT) in the synaptic vesicles with IHC, contrasting, e.g.,
the KMnO4 method for NA (Figure 1D). So perhaps IHC
also failed to demonstrate neuropeptides in synaptic vesicles?
Therefore, subcellular fractionation studies were carried out,
strongly suggesting lack of peptide in the synaptic vesicle
pool but presence of NPY in the fraction with many LDCVs
(Figures 2A–E) (Lundberg et al., 1981; Fried et al., 1985)3. In
contrast to monoaminergic neurons, in sensory glutamatergic
neurons the amino acid appears to be exclusively stored in
synaptic vesicles (Merighi, 2002) (Figures 1C,E).
Furthermore, peptides are in general released when neurons
fire at high frequency or in bursts (Lundberg et al., 1980;
Andersson et al., 1982; Bondy et al., 1987; Bartfai et al., 1988;
De Camilli and Jahn, 1990; Verhage et al., 1991; Consolo et al.,
1994; Xia et al., 2009), and often extrasynaptically (Zhu et al.,
1986) (Figure 3). The latter was already indicated in a pioneering
study on the presynaptic structure of the synapse, showing
docking sites for the synaptic vesicles which, however, are not
spacious enough to leave room for LDCVs which are twice-the-
size (1,000 Å) (Pfenninger et al., 1969) (Figure 3)4. This is of
course not valid for somato-dendritic release and where true
synapses do not exist, nor for the peripheral autonomic nervous
system, where there is a considerable distance between the nerve
ground plexus (Hillarp, 1949; Falck, 1962) and the smooth
3The preparation used in Fried et al. (1985) was very suitable for the purpose: The
muscle layer of rat vas deferens contains a dense network of noradrenergic nerve
terminals storing NPY (Figures 2A–C). However, the very thick, compact smooth
muscle layer makes isolation of nerves/storage vesicles difficult. This obstacle was
circumvented by castrating rats which leads to muscle atrophy. Thus, fairly pure
fractions containing, respectively, synaptic and large vesicles, many of the latter
with a visible dense core (Figure 2E), could be obtained (Fried et al., 1985).
4Of note, Figure 24–4A in Chapter 24 by A. I. Basbaum and T. M. Jessell shows an
electron micrograph of an afferent C fiber nerve ending making a type 1 synapse
with a dendrite in the monkey superficial dorsal horn. Here a string of LDCVs are
seen close to the presynaptic membrane opposite to the postsynaptic density. It is
not possible to definitely decide, if the LDCVs reach the presynaptic membrane.
Nevertheless, the ‘rule’ of extrasynaptic release of LDCVs may not be without
exceptions. The micrograph is by courtesy of H. J. Ralston, III. [from the Fourth
Edition of the Textbook “Principles of Neural Science” (2000), edited by E. R
Kandel, J. H. Schwartz and T. M. Jessell.]
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FIGURE 1 | Immunofluorescence micrographs of the guinea-pig inferior mesenteric ganglion (A,B) and electron micrographs from different types of nerve endings
(C–E). (A,B) Two adjacent sections incubated with antibodies to somatostatin (A) and the noradrenaline (NA) synthesizing enzyme dopamine ß-hydroxylase (DBH)
(B). The majority of the principal ganglion cells are somatostatin-positive, whereas the small intensely fluorescent (SIF) cells (asterisk) lack the peptide. Virtually all
ganglion cells and the SIF cells are DBH-positive, i.e., are noradrenergic. (C–E) Examples of transmitter storage in nerve endings based on or immunohistochemistry
(C,E) or potassium permanganate fixation (D). (D) In sympathetic nerve endings NA (black precipitate) is stored in both (small) synaptic vesicles and large dense
core vesicle (LDCVs) (arrow). Note that content varies between vesicles, both in the synaptic and LDCVs. (C) Substance P, a neuropeptide (black precipitate), in a
sensory nerve ending in the monkey dorsal horn, is stored exclusively in LDCVs, all synaptic vesicles are empty. (E) Peptide and glutamate co-storage and
coexistence in the dorsal horn of the rat spinal cord based on immunogold immunohistochemistry. Substance P/CGRP is detected with 10/20 nm gold particles and
glutamate with 5 nm gold particles. Note that substance P and CGRP can be stored within the same LDCV (left box, magnified in E’). Staining for glutamate is
restricted to synaptic vesicles (right box, magnified in E”). The results suggest that glutamate, a small molecule transmitter, is not stored in LDCVs in sensory nerve
endings, and release of peptide and amino acid may be separate events. This contrasts NA (see D). Bars: 40 µm, for (A,B); 100 nm for (C,D); 250 nm for (E). (A,B)
From Hokfelt et al. (1977a). (C) From DiFiglia et al. (1982), with permission. (D,E) Courtesy of Dr. A. Merighi (cf., Merighi, 2002).
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FIGURE 2 | Coexistence and subcellular distribution of neuropeptide Y (NPY)
and noradrenaline (NA) in the rat vas deferens. (A,B) Immunohistochemical
visualization of NPY- (A) and tyrosine hydroxylase (TH)-(B) positive nerve
terminals in adjacent sections. Overlapping, dense NPY and noradrenergic
networks are seen in the muscle layer. Note sparse NPY-only positive nerves
(arrow) in the subepithelial region, possibly cholinergic nerves. (C) Electron
microscopic micrograph of several nerve terminal profiles in the muscle layer
after potassium permanganate (KMnO4) fixation, showing small synaptic
vesicles with a dense core and LDCVs. The dense core indicates presence of
NA both in the synaptic and LDCVs (cf. Figure 1D). No profiles without small
vesicle with a dense core are seen, suggesting a pure adrenergic innervation
of the muscle layer. (D,E) Subcellular distribution of NA (x) and NPY (o) in a
density gradient of rat vas deferens. There is only one peak for NPY (fraction
7; E), whereas there are two peaks for NA (fraction 5 and 7), tentatively
representing synaptic vesicles and LDCVs, respectively. Note many LDCVs
(arrows), as well as many vesicles of the same size but without dense core
(double-headed arrow). The peptide is only present in the heavy fraction (in
agreement with Figures 1C,E), whereas NA is present also in the light one (in
agreement with Figure 1D). On the abscissa, totally recovered sedimentable
substance is given as picomoles per milliliter after centrifugation at
145,000 × gmax for 45 min. On the ordinate, density gradient fractions 1–10
are given, corresponding to the following sucrose molarities: 1 (0.26 M), 2
(0.32 M), 3 (0.47 M), 4 (0.56 M), 5 (0.69 M), 6 (0.74 M), 7 (0.84 M), 8 (0.91 M),
9 (0.98 M), 10 (1.2 M). Recoveries of NA = 70%, of NPY = 65%, and of
protein = 87%. Reprinted from Fried et al. (1985), with permission.
muscle cells, as shown with electron microscopy combined with
electrophysiology (Merrillees et al., 1963). Furthermore, in the
brain, extrasynaptically released neuropeptides may diffuse over
long distances, so called volume transmission (Fuxe et al., 2010).
The exocytotic machinery underlying neurotransmitter
release has been thoroughly characterized with regard to release
of small molecule transmitters stored in synaptic vesicles (De
Camilli and Jahn, 1990; Sudhof, 2014). However, the exocytotic
neuropeptide release from LDCVs is less well defined. In early
studies on synaptosomes it was shown that CCK release from
LDCVs is triggered by small elevation of Ca2+ concentration in
the bulk cytoplasm, whereas glutamate release from the synaptic
vesicles requires the higher concentrations produced close to
Ca2+ channels in the active zone (Verhage et al., 1991). This is
in agreement with the localization of the two types of vesicles
consistently observed in electron microscopic micrographs of
the nerve endings: many synaptic vesicles with some close to
the presynaptic membrane, versus a few LDCVs virtually always
distant from the synapse (Figure 3).
There is evidence for involvement of SNAREs [soluble N-ethyl
maleimide (NEM)-sensitive factor attachment protein receptor
protein family] (Sudhof, 2014) also in dendritic release from
magnocellular dendrites (Schwab et al., 2001; de Kock et al., 2003;
Ovsepian and Dolly, 2011). The calcium-dependent activator
protein for secretion (CAPS) (Walent et al., 1992) has been
identified as a priming factor for exocytosis of LDCVs (Stevens
and Rettig, 2009; James and Martin, 2013). Thus CAPS2, but not
CAPS1, is required for LDCV exocytosis as shown in cerebellar
granule cells and hippocampal interneurons (Sadakata et al.,
2004; Shinoda et al., 2011).
Taken together, these early findings suggested that
neuropeptides were not the main neuronal messengers.
Moreover, when neuropeptides are released, the fast small
molecule transmitters are already active in the synaptic cleft –
i.e., no peptide release without release of classic transmitters. The
discovery of coexistence and co-transmission was summarized
in several books/reviews (Burnstock, 1978; Hokfelt et al.,
1980a, 1986, 1987a; Cuello, 1982; Chan-Palay and Palay, 1984;
Jaim-Etcheverry, 1994; Merighi, 2002), and since then further
efforts have been made to understand co-signaling involving
neuropeptides, including co-release of both an excitatory and an
inhibitory neuropeptide. For an up-to-date overview of many
aspects on neuropeptide signaling (see e.g., Salio et al., 2006; van
den Pol, 2012; Ludwig et al., 2016).
More recently it has become clear that coexistence of small
molecule transmitters, encompassing various combinations of
GABA, glycine, glutamate, dopamine and acetylcholine (e.g.,
Guiterrez, 2009; Hnasko and Edwards, 2012; Trudeau et al., 2014)
(Figure 3). For example, coexistence of GABA and glycine was
first reported in the cerebellum (Ottersen et al., 1988), and then
in the spinal cord (Todd and Sullivan, 1990; Ornung et al., 1994),
where evidence for GABA-glycine co-transmission was obtained
in the dorsal horn, and possible co-release from the same synaptic
vesicles (Jonas et al., 1998) (Figure 3). Moreover, mesencephalic
dopamine neurons can also release glutamate (Hnasko et al.,
2010) and GABA (Tritsch et al., 2012), whereby GABA is
Frontiers in Neural Circuits | www.frontiersin.org 7 December 2018 | Volume 12 | Article 106
fncir-12-00106 December 21, 2018 Time: 15:28 # 8
Hökfelt et al. Galanin-Noradrenaline Coexistence and Major Depression
FIGURE 3 | Cartoon showing coexistence of a neuropeptide with classic and ‘unconventional’ neurotransmitters in a nerve ending synapsing on a dendrite. Two
types of storage vesicles are shown: synaptic vesicles (diameter 500 Å) storing classic transmitters (e.g., 5-HT, NA, GABA or glutamate), mainly released at
synapses; large dense core vesicles (LDCVs) storing neuropeptides and, in amine neurons NA or 5-HT. The peptides are in general released extrasynaptically
(“volume transmission”), when neurons fire with high frequency or in bursts. Peptide receptors are essentially extrasynaptic or presynaptic, whereas ligand-gated
receptors are mostly localized in the postsynaptic membrane. ‘Gaseous’ (e.g., nitric oxide, NO) and other non-conventional transmitters are not stored in vesicles,
but are generated upon demand (Snyder and Ferris, 2000). The presynaptic grid, an egg basket-like structure, originally described by Pfenninger et al. (1969), is
indicated in the nerve ending and high-lighted to the right. Note that the LDCV does not fit into the grid and thus cannot attach to the presynaptic membrane for
release. In contrast, there is room for the synaptic vesicle. This supports the concept that peptides are mostly not released into the synaptic cleft. Drawing by Mattias
Karlen. Modified from Pfenninger et al. (1969),Lundberg and Hokfelt (1983), and Lang et al. (2015).
not synthesized via the classic enzyme glutamate decarboxylase
(GAD) but via aldehyde dehydrogenase 1a1 (Kim et al., 2015).
Thus, the number and combinations of transmitters
present in a nerve ending (and/or dendrites) virtually
seem endless, and it is difficult to define rules according
to which neurotransmitters co-exist and are involved in co-
transmission, as is discussed further in this Frontiers special
topic. Furthermore, neurotransmitter switching, the gain of one
and loss of another transmitter in the same, mammalian neuron,
can occur not only during development but also in adult animals
(Spitzer, 2017).
There is an increasing interest in neuropeptide/neurotrans-
mitter coexistence and a need to explore transcriptional changes
in defined healthy and diseased brain circuitries (Akil et al.,
2010). In fact, there are many interesting results from animal
disease models, suggesting involvement of neuropeptides and
neuropeptide coexistence in patho-physiological processes with
potential therapeutic implications. However, information on the
significance of transmitter and neuropeptide coexistence in the
normal and diseased human nervous system is limited. In this
article, the focus is on galanin co-existing in noradrenergic
neurons in the LC, and on galanin receptor expression in
postmortem brains from normal subjects and depressed patients
who committed suicide (Le Maitre et al., 2013; Barde et al.,
2016). This is in line with previous extensive work carried out on
postmortem brains from depressed humans, showing changes in
transcripts related to neurotransmitters/neuropeptides and their
receptors and to transporters, growth factors in nerve cells, and
in glia, in cortical, limbic, hypothalamic and lower brain stem
regions (Evans et al., 2004; Iwamoto et al., 2004; Aston et al.,
2005; Choudary et al., 2005; Kang et al., 2007; Anisman et al.,
2008; Kozicz et al., 2008; Tochigi et al., 2008; Klempan et al.,
2009; Sequeira et al., 2009, 2012; Sibille et al., 2009; Poulter et al.,
2010; Bernard et al., 2011; Bloem et al., 2012; Kerman et al., 2012;
Zhurov et al., 2012; Labonte et al., 2013, 2017; Li et al., 2013; Du
et al., 2014; Lopez et al., 2014a,b; Hayley et al., 2015; Maheu et al.,
2015; Torres-Platas et al., 2016; Roy et al., 2017).
GALANIN
Galanin was originally isolated from porcine intestine as a 29-
amino acid (30 in humans) neuropeptide (Tatemoto et al., 1983;
Schmidt et al., 1991) (Figure 4A) with a wide distribution in the
rat brain as shown with RIA (Skofitsch and Jacobowitz, 1986),
IHC (Rokaeus et al., 1984; Melander et al., 1985, 1986b,c,d;
Skofitsch and Jacobowitz, 1985; Merchenthaler et al., 1993), and
ISH (Gundlach et al., 1990b; Jacobowitz and Skofitsch, 1991;
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FIGURE 4 | (A) Structure of galanin in three species. Galanin is composed of 29 amino acids in most species, except humans (30 amino acids). Note conservation
of N-terminal portion. (B) Signaling pathways of galanin receptor subtypes. Galanin, via GalR1 and GalR3, opens potassium channels leading to membrane
hyperpolarization. Galanin can via GalR2 activate PLC resulting in generation of IP3, release of Ca2+ from the smooth endoplasmic reticulum, opening of Ca2+
channels and eventually transmitter release. AC, adenylate cyclase; cAMP, 3′, 5′-cyclic adenosine monophosphate; DAG, diacylglycerol; K+, G-protein-regulated
inwardly rectifying potassium channel; sER, smooth endoplasmic reticulum; IP3, inositol triphosphate; PIP2, phosphatidylinositol bisphosphate; PKC, protein kinase
C; PLC, phospholipase C. Modified from Iismaa and Shine (1999) and Lang et al. (2015). Drawing by Mattias Karlén.
Jacobowitz et al., 2004). The distribution of galanin in the mouse
brain is similar to that in rat, both with regard to galanin peptide
(Perez et al., 2001) and to its mRNA (Cheung et al., 2001;
Lein et al., 2007). The galanin system has also been characterized
in the monkey brain (Melander and Staines, 1986; Kordower and
Mufson, 1990; Walker et al., 1991) (for human brain, see below).
For many years galanin was considered as the sole endogenous
ligand for GalR1-3 but more recently additional ligands
were described (Lang et al., 2015)5. Currently, three galanin
receptors, GalR1-3, have been cloned, all three belonging to the
family of seven transmembrane-spanning GPCRs, with different
transduction mechanisms, with GalR1 and -R3 having distinct
similarities (Habert-Ortoli et al., 1994; Fathi et al., 1997; Howard
5First to be identified was the galanin message-associated peptide (GMAP), a
product generated from the same precursor as galanin (Rokaeus and Brownstein,
1986). In brain it was also recognized that the N-terminal fragment galanin (1–
16), conserved throughout species, is recognized by high affinity receptor sites
in the forebrain (Fisone et al., 1989), and subsequently other fragments have
been identified in the brain (Sillard et al., 1992; Ihnatko and Theodorsson, 2017).
Almost 20 years ago the galanin-like peptide (GALP) was discovered in the porcine
hypothalamus and shown to be an endogenous ligand of GalR2 (Ohtaki et al.,
1999). GALP (9–21) is identical to galanin (1–13) with a high sequence homology
among species. In the analysis of ganglioneuroma tissues Santic and colleagues
discovered a splice variant of GALP mRNA, a 25 amino acid peptide and named it
Alarin (Santic et al., 2006). This peptide, however, does not bind to any of the three
galanin receptors, but still is considered a member of the galanin family (Lang et al.,
2015). More recently it was found that spexin, a 14-amino acid peptide, is a ligand
at the GalR2 and -R3 receptors (Kim et al., 2014).
et al., 1997; Wang et al., 1997; Ahmad et al., 1998; Smith et al.,
1998; Iismaa and Shine, 1999; Branchek et al., 2000; Lang et al.,
2007, 2015) (Figure 4B). The three galanin receptors are present
in most parts of the rat brain, but could not be detected e.g.,
in dorsal cortical areas and the hippocampal formation (HiFo)
in early autoradiographic ligand binding studies (Skofitsch et al.,
1986; Melander et al., 1986a, 1988).
Galanin receptors have also been mapped in the mouse brain
using 125I-galanin binding autoradiography (Jungnickel and
Gundlach, 2005). A direct comparison with results in rat in the
study by, e.g., O’Donnell et al. (2003) reveals an overall similar
distribution but with some remarkable, apparently qualitative
species differences. Thus, mouse shows, i.a., a strong signal in two
important regions, the striatum and the cerebellum (Jungnickel
and Gundlach, 2005) which both lack binding in the rat (Skofitsch
et al., 1986; Melander et al., 1988; O’Donnell et al., 2003). To our
knowledge, no attempts have been made to identify the cellular
localization and origin of, e.g., the structures binding galanin in
the mouse striatum.
The cloning of the receptors allowed localization with ISH and
qPCR, which revealed that the transcripts for GalR1 and GalR2
are widely distributed in the rat brain, primarily in the brain
stem and in ventral cortical areas (Landry et al., 1998; Mitchell
et al., 1999; O’Donnell et al., 1999, 2003; Burazin et al., 2000;
Waters and Krause, 2000; Mennicken et al., 2002). However,
the GalR2 transcript is transiently highly expressed in neocortex
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during the first week after birth (Burazin et al., 2000). The
distribution of GalR3 is limited (Mennicken et al., 2002). Only
the GalR1 transcript has been mapped with ISH in the mouse
brain (Hohmann et al., 2003; Lein et al., 2007). Thus, The Allen
Brain Atlas (Lein et al., 2007) lacks results on GalR2 or GalR3,
suggesting that they are expressed at low levels. This is also
supported by the demonstration that the 125I-galanin binding
sites are absent in a GalR1 knock-out mouse (Jungnickel and
Gundlach, 2005). Taken together, these results suggest that GalR1
is the predominant receptor in the mouse brain, and that distinct
species differences exist between mouse and rat.
GalR3 has emerged as a complex receptor (Lang et al.,
2015), not present in all mammals (Liu et al., 2010). Its
signaling properties are still not well defined, even though GalR3-
transfected cell lines have now been generated (Lu et al., 2005b;
Robinson et al., 2013). However, these cells could so far not
be used for stable signaling experiments (see Lang et al., 2015).
Still, GalR3 presumably acts via a PTX sensitive Gi/o-type G
protein which in turn regulates inwardly rectifying K+ channels
(Smith et al., 1998), as do GalR1 receptors (Smith et al., 1998)
(Figure 4B). This lack of knowledge contrasts the substantial
information about GalR1 and GalR2 (see Lang et al., 2015). The
cloning of the receptors was useful, also because it has been
difficult to raise specific antibodies to GalR1-3 (Lu and Bartfai,
2009; Brunner et al., 2018). A similar situation exists for other
GPCRs (Michel et al., 2009). Detailed tables on the distribution
of galanin and GalR1-3 in rodent brain are found in O’Donnell
et al. (1999, 2003), Burazin et al. (2000), Hohmann et al. (2003),
and Jungnickel and Gundlach (2005).
Early research on galanin was initiated because of its strong
reaction to nerve injury. Transection of the sciatic nerve in
rat causes an >100-fold increase in galanin synthesis (mRNA
and peptide levels) in the corresponding somata of DRG
somata (Hokfelt et al., 1987b). Upregulation could also be
detected in the brain after various types of injury/manipulations
(Cortes et al., 1990a,b; Villar et al., 1990; Agoston et al.,
1994; Palkovits, 1995). In fact, galanin meets the criteria of a
neurotransmitter/-modulator, but also has trophic functions, as
shown both in brain and the peripheral nervous system (Hobson
et al., 2010). Galanin has, in fact, many characteristics similar
to the brain-derived neurotrophic factor (BDNF), including
storage in, and exocytotic release from LDCVs and both
transmitter and trophic functions (Barde, 1994). For example,
galanin affects spine density (Sciolino et al., 2015), and it
is well-known that BDNF influences dendritic morphology
(Bennett and Lagopoulos, 2014). Thus, trophic functions of
galanin are potentially interesting but will not be discussed
here.
A further early finding in the rat was the coexistence
(Figures 5A,B”) of galanin (Figure 5B) in both noradrenergic
neurons in the LC (Figure 5B’) (Rokaeus et al., 1984;
Skofitsch and Jacobowitz, 1985; Melander et al., 1986b,c;
Holets et al., 1988; Moore and Gustafson, 1989) and in
serotonergic neurons in the dorsal raphe nucleus (DRN)
(Melander et al., 1986c; Fuxe et al., 1990; Priestley et al., 1993;
Xu and Hokfelt, 1997), two systems associated with mood-
related behavior. The LC neurons also express transcripts for
both GalR1 and -R2 (O’Donnell et al., 1999; Burazin et al.,
2000).
Thereafter galanin biology has since the early 1990’s been
regularly summarized in books/journal from meetings (Hökfelt
et al., 1991, 1998; Hökfelt and Crawley, 2005; Hokfelt, 2010;
Hokfelt and Tatemoto, 2010); and in peer-reviewed articles
focusing on the nervous system (only such published after 2004,
and not included in the books/journals cited above, are listed
here) (Lundstrom et al., 2005; Holmes and Picciotto, 2006;
Karlsson and Holmes, 2006; Ogren et al., 2006, 2007, 2010;
Robinson et al., 2006; Walton et al., 2006; Wrenn and Holmes,
2006; Lu et al., 2007; Tortorella et al., 2007; Picciotto, 2008;
Robinson and Brewer, 2008; Butzkueven and Gundlach, 2010;
Picciotto et al., 2010; Webling et al., 2012; Diaz-Cabiale et al.,
2014; Freimann et al., 2015; Weinshenker and Holmes, 2016;
Millon et al., 2017a; Genders et al., 2018a); and in some major
comprehensive reviews (Lang et al., 2007, 2015).
GALANIN INHIBITS RAT LOCUS
COERULEUS NEURONS
Locus coeruleus is a small, compact bilateral nucleus in the pons
located in the gray matter close to the lateral aspect of the 4th
ventricle (Maeda, 2000). Dahlstrom and Fuxe first reported that
NA is a transmitter in the rat LC, a.k.a. the A6 group (Dahlstrom
and Fuxe, 1964). They used the formaldehyde, or Falck-Hillarp,
fluorescence method that allows microscopic visualization of
catecholamines and serotonin in tissue sections (Carlsson et al.,
1962; Falck, 1962; Falck et al., 1962).
In the rat, the LC contains 2,800–3,600 neurons (both sides)
(with an additional 260 neurons in the subcoeruleus area, the
vast majority of which are noradrenergic with wide projections
to virtually all parts of the central nervous system (Ungerstedt,
1971; Descarries and Saucier, 1972; Swanson and Hartman, 1975;
Swanson, 1976; Morrison et al., 1978; Moore and Bloom, 1979;
Goldman and Coleman, 1981; Foote et al., 1983; Aston-Jones
et al., 1995). NA nerve terminals are also extensively present in
primate cortex (Lewis et al., 1986).
When explored with electrophysiological methods galanin has
effects on the membrane potential of several neuron systems
(see Xu et al., 2005). Galanin hyperpolarizes noradrenergic LC
neurons in a slice preparation (Seutin et al., 1989; Sevcik et al.,
1993; Pieribone et al., 1995), mediated via GalR1 (Ma et al.,
2001) (Figure 5C). However, the GalR2 (R3) agonist ARM-1986
(Liu et al., 2001; Lu et al., 2005b) does not cause any effect on
the membrane potential (Ma et al., 2001) (Figure 5C). GalR2
may instead have a presynaptic role in the projection areas
of LC neurons, perhaps mainly acting as an autoreceptor (Ma
et al., 2001). In agreement, galanin is present in noradrenergic
[dopamine ß-hydroxylase (DBH)]-positive nerve terminals in
cortex and the hippocampus (Melander et al., 1986d; Xu et al.,
1998). Galanin activation of GalR1, but not -R2 or R3, has
been shown also in other studies on the rat and mouse LC
(Hawes et al., 2005; Mitsukawa et al., 2009). In addition to this
direct effect, galanin at low concentrations (10−9M) enhances the
autoinhibitory effect of NA on LC neurons via alpha-2A receptors
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FIGURE 5 | (A–B”) Immunofluorescence micrographs of the dorsal pontine periventricular region of mouse after double-staining of a section with antibodies to
galanin (green) and tyrosine hydroxylase (TH) (red), the rate-limiting enzyme for catecholamine synthesis and thus a marker for NA neurons. Note that both antibodies
stain neurons in the locus coerulus (LC) (B,B’), whereby many (yellow, B”), but not all TH-positive neurons express galanin [arrowheads point to TH-only neurons
(red), apparently lacking galanin] (B’). Galanin is also present in many structures outside the LC. Colchicine treated animal. Courtesy Joanne Bakker and Mingdong
Zhang. Bar for (A) 200 µm, for (B–B”) 20 µm. (C) Effect of galanin and the GalR2 agonist AR-M1896 on LC neurons (upper two traces), and the dose–response
curves of galanin (red), the AR-M1896 (green) and the mixed GalR1-GalR2 M961 agonist (magenta) (lower trace). Note strong hyperpolarization of galanin and a less
strong effect of M961, whereas that AR-M1896 hardly causes any effect at all. From Ma et al. (2001). (D, left panel) Effect of galanin on the response of LC neurons
to NA. NA (applied from a pipette at the arrowhead) induces a persistent outward current (upper trace). When galanin (0.1 nM) is present, the NA-induced outward
current is enhanced, and the duration is prolonged (middle trace). After wash out of galanin, the amplitude and duration of the NA response was similar to that seen
before galanin administration (lower trace). (D, right panel) Effect of galanin on dose-response (upper figure) and duration (lower figure) of NA. The NA dose-response
curve is shifted to the left, when galanin (0.1 nM) is present (upper figure). The duration of the NA-induced current is increased in the presence of galanin (lower
figure). ∗∗P < 0.01. From Xu et al. (2001) with permission.
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(Xu et al., 2001) (Figure 5D). This may in fact be the primary
action of galanin in controlling the firing of LC neurons. Thus,
galanin can via different autoinhibitory mechanisms exert a two-
step inhibition on LC neurons, at low concentrations enhancing
the inhibitory alpha-2A receptor effect.
Autoinhibition of LC neurons, mediated by NA via alpha-
2A receptors, was early discovered by Svensson et al. (1975) and
Aghajanian et al. (1977). It is assumed that autoinhibition, both
at NA and serotonin neurons, at least in part, is responsible
for the delayed onset of the clinical effect of monoamine
reuptake inhibitors (Artigas et al., 1996; Mongeau et al., 1997;
Millan, 2006). Autoinhibition via NA in LC was originally
suggested to be a consequence of the release from collaterals
(Aghajanian et al., 1977). There is, however, evidence that
NA can be released from soma/dendrites (Pudovkina et al.,
2001; Pudovkina and Westerink, 2005), and more recently
release was shown to occur from individual vesicles by
combined measurements using amperometry and patch clamp
methodologies (Huang et al., 2007). This is in agreement with
electron microscopic analysis, showing synaptic vesicles with
a dense core in LC dendrites (Shimizu et al., 1979). Thus,
collaterals are not necessarily the only structure involved in the
autoinhibition.
There is another source of catecholamine input to the LC
neurons originating from one of the three C neuron groups
in the medulla oblongata: adrenaline (epinephrine) containing
afferents (Figure 6) (Hokfelt et al., 1974b, 1984; Howe et al., 1980;
Armstrong et al., 1982), which synapse on LC dendrites (Milner
et al., 1989). This was supported by early tracing experiments,
although at that time no transmitter histochemical identification
was performed (Cedarbaum and Aghajanian, 1978). One likely
origin is C1 neurons, since they display a high degree of
collateralization, including inputs to the LC (Figure 6) (Haselton
and Guyenet, 1990).
Early studies suggested that the adrenaline (Cedarbaum and
Aghajanian, 1976) and the C1 neurons (Aston-Jones et al., 1991)
inhibit LC neurons. However, the more recent discovery that the
C1 neurons are glutamatergic together with optogentic analysis
demonstrated excitation as the primary effect (Figure 6) (Abbott
et al., 2012). Released adrenaline may act as a modulator not
only on postsynaptic but also presynaptic (Li et al., 1995) alpha-
2A receptors, which will, respectively, directly and indirectly,
dampen LC neuron activity (Figure 6) (Guyenet et al., 2013).
Taken together, galanin prevents overexcitation of LC, but is
only one of several molecules performing this task (Aston-Jones
et al., 1991; Singewald and Philippu, 1998; Van Bockstaele, 1998;
Berridge and Waterhouse, 2003; Van Bockstaele and Valentino,
2013). This comprehensive network is perhaps a sign of how
important it is to balance the activity of the noradrenergic LC
neurons, which are involved in the control of many bodily
functions (see below).
Kehr and colleagues have analyzed the effect of
intracerebroventricularly administered galanin in freely moving
rats and mice, monitoring several neurotransmitters using
in vivo microdialysis (Ungerstedt, 1984) and a sensitive HPLC
method. Their studies indicate that galanin reduces basal and
desipramine-induced extracellular NA levels (Yoshitake et al.,
2003, 2004). This effect is assumed to be exerted via GalR1 at the
noradrenergic cell bodies/dendrites in the LC.
Galanin and Dendritic Release
Studies on the hypothalamic magnocellular hormones
vasopressin and oxytocin have provided compelling evidence
that these two peptides are not only released from nerve endings
in the posterior pituitary but also, independently, from dendrites
in the paraventricular and supraoptic nuclei (Morris et al., 1998;
Landgraf and Neumann, 2004; Ludwig and Leng, 2006; Kennedy
and Ehlers, 2011; Ovsepian and Dolly, 2011; Ludwig et al., 2016).
There is evidence for involvement of SNAREs [soluble N-ethyl
maleimide (NEM)-sensitive factor attachment protein receptor
protein family] (Sudhof, 2014) in release from magnocellular
dendrites (Schwab et al., 2001; de Kock et al., 2003; Ovsepian
and Dolly, 2011). Results from studies on CAPS2-dependant
neuropeptide release from soma of dorsal root ganglion neurons
(Bost et al., 2017; Shaib et al., 2018) may also be relevant for
dendritic/somatic release in the brain. Galanin may be released
from soma and dendrites in the LC (Pieribone et al., 1995;
Vila-Porcile et al., 2009) (Figure 6). Therefore, it has been
hypothesized that stress-induced firing increases galanin release
from nerve terminals in the forebrain and dendrites-soma of LC
neurons. This could lead to activation of GalR1 autoreceptors
and inhibition of firing of LC neurons, a possible mechanism
involved in resilience and development of depression-like
behavior in animals (Sciolino et al., 2015) (see below).
Other Co-transmitters in the LC
Neuropeptide Y is expressed in LC neurons in rat (Everitt et al.,
1984; Chronwall et al., 1985; Yamazoe et al., 1985; Holets et al.,
1988) and human (Chan-Palay et al., 1990). Recently it has been
shown in mice that dopamine is co-released with NA in the
hippocampus (Kempadoo et al., 2016; Takeuchi et al., 2016)
and the paraventriculer thalamic nucleus (Beas et al., 2018)




Galanin influences mood-related behavior in a region-specific
way (Bing et al., 1993; Moller et al., 1999). Moreover, results from
a number of rat experimental models suggest that galanin can
be both prodepressive/anxiogenic and antidepressive (Fuxe et al.,
1990, 1991, 1998; Weiss et al., 1998, 2005; Bellido et al., 2002;
Khoshbouei et al., 2002; Barrera et al., 2005; Sergeyev et al., 2005;
Lu et al., 2005a, 2007, 2008; Holmes and Picciotto, 2006; Karlsson
and Holmes, 2006; Ogren et al., 2006; Kuteeva et al., 2008, 2010;
Kozlovsky et al., 2009; Picciotto et al., 2010; Le Maitre et al., 2011;
Sciolino et al., 2012, 2015; Weinshenker and Holmes, 2016).
In many of the early studies listed above on depressive-
like behavior the receptor involved was not identified, or the
site of action was not defined experimentally, but there was a
general consensus that it is GalR1 that mediates the depressive
behavior and that GalR2 may be prodepressive (summarized in
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FIGURE 6 | Cartoon showing several transmitters and signaling pathways in the locus coeruleus (LC) (part of a cell body with initial axon and an afferent nerve
ending and a possible axon collateral). A noradrenergic LC neuron co-expresses galanin (yellow LDCVs) originating in the Golgi complex. The peptide in the LDCVs
is, after transport to the somatic and dendritic cell membrane, released by exocytosis. Galanin then acts on inhibitory autoreceptors (GalR1/R3), opening potassium
channels, in this way attenuating noradrenaline (NA) release in the forebrain. Galanin at low concentrations enhance the alpha2A mediated inhibition of the LC neuron
(by an unknown mechanism). Galanin could also be released from collaterals. The GalR3 antagonist (SNAP 398299) may exert an antidepressive action by
disinhibiting the LC neuron and restituting forebrain NA levels. With regard to small transmitters, NA (purple triangles) can be released from soma-dendrites and
collaterals, acting on somato-dendritic, postsynaptic and presynaptic alpha2A receptors. The afferent nerve ending originates from C1 neurons which are
glutamatergic (red dots) and co-release adrenaline (red triangles). Also adrenaline can act on the alpha2A receptors. The basis for this cartoon is animal experiments,
and in the case of the galanin system, results from human postmortem brains are also incorporated.
Mitsukawa et al., 2009; Kuteeva et al., 2010; Hoyer and Bartfai,
2012; Webling et al., 2012; Freimann et al., 2015).
Two recent studies support involvement of GalR1, and suggest
the ventral periaqueductal gray as one likely site of action.
Using a rat model of depression based on chronic mild stresses
(CMS) (Willner et al., 1987; Moreau et al., 1992), behavior was
evaluated in the open field test, the forced swim test (FST), and by
monitoring sucrose consumption (Wang et al., 2016). Transcript
levels of galanin and GalR1-3 in various, laser-dissected brain
regions, including the hippocampal formation (HiFo), vPAG,
the DRN and the LC were analyzed with quantitative real time
PCR (qPCR) (Wang et al., 2016). Only GalR1 mRNA levels
were significantly changed (increased), in a single region, the
vPAG. Moreover, after knocking down GalR1 in the vPAG
using siRNA, the depressive behavioral phenotypic parameters
were similar to unstressed controls. This result suggested that
the depression-like behavior in rats exposed to CMS is likely
related to an elevated expression of GalR1 in the vPAG. The
phenotype of the GalR1-positive neurons was not identified,
despite comparing their distribution with serotonin, glutamate
(vesicular glutamate transporter type 2, VGLUT2) and GABA
(glutamic acid decarboxylase, GAD) neurons (Wang et al.,
2016).
In another study, the galanin system was monitored with
qPCR, ISH and RIA methodologies following mild blast-induced
traumatic brain injury (mbTBI) (Kawa et al., 2016). Significant
increases in galanin peptide and transcript were observed in the
LC, at 1 day with qPCR, at 3 days with RIA and from 2 h to
7 days with ISH. The increases thus remained for 7 days (ISH)
(the longest period studied). With regard to galanin receptors,
GalR1 mRNA was significantly increased in vPAG at 1 and 7 days,
likely in the same neuron population as seen in the CMS model
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(Wang et al., 2016). These findings suggest a long-lasting role for
the galanin system in the endogenous response to mbTBI. Again,
the phenotype of these GalR1-positive neurons was not identified.
Nevertheless, in both cases stress, and possibly depression-like
behavior, are associated with increased levels of GalR1 transcript
in the vPAG. Interestingly, the galanin system has also been
shown to modulate stress-related responses related to mild TBI in
a model of postraumatic stress disorder (PTSD) (Kozlovsky et al.,
2009).
The robust and lasting effect of mbTBI on the expression of
galanin (at least 7 days) not only in LC but also in 5-HT neurons
(Kawa et al., 2016) is more sustained than the transient increase in
tyrosine hydroxylase (TH) (3 days) and tryptophan hydroxylase 2
(1 day) seen in the same mbTBI model (Kawa et al., 2015). Thus,
in mbTBI the coexisting peptide may have a more long-lasting
and important effect than the small molecule transmitter.
In another study, i.p. injection (a stress by itself) and swim
stress increased both galanin and TH mRNA levels in the LC,
but not TPH2 or galanin transcripts in the DRN (Kuteeva et al.,
2008), indicating that the serotonergic system is less sensitive to
stress than the noradrenergic system. This has also been shown in
other studies employing different types of stress (e.g., Wilkinson
and Jacobs, 1988; Jordan et al., 1994; Kuteeva et al., 2008, 2010).
The long lasting effects of stress can also be gauged against the fact
that peptides can exert effects over long periods of time (Herbert,
1993; van den Pol, 2012). One example is a study on the lamprey
locomotor network that revealed that a 10-min administration
of substance P causes a long-lasting (>24 h) modulation of the
frequency and regularity of NMDA-evoked locomotor bursts
(Parker and Grillner, 1999).
GalR2 may also be involved, but here an opposite effect
has been recorded, i.e., galanin actions via this receptor are
antidepressive (Gottsch et al., 2005; Lu et al., 2005a, 2007,
2008; Kuteeva et al., 2008, 2010; Kinney et al., 2009; Le
Maitre et al., 2011; Saar et al., 2013a,b; Kawa et al., 2016),
in some cases associated with the vPAG. For example, in a
neuropharmacological study (Kuteeva et al., 2008) the time
of immobility (Figure 7A) and climbing (Figure 7B) were
recorded in the FST. Galanin, the GalR1 receptor agonist
M617, the GalR2(R3) agonist AR-M1896, the GalR2 antagonist
M871 or aCSF were infused intracerebroventricularly. Galanin
significantly increased immobility time, as did the GalR1 receptor
agonist M617 (Figure 7A). In contrast, the GalR2(R3) agonist
AR-M1896 decreased immobility, similar to fluoxetine, whereas
the GalR2 antagonist M871 increased the time of immobility.
Together these results support the view of GalR1 being pro- and
GalR2 antidepressive. Moreover, the antidepressive effect of the
GalR2 antagonist suggests there is an in vivo, tonic activation
of this receptor under forced swimming (stress). This provides
further evidence that galanin is released in vivo under stressful
conditions. More recently it has been shown that an anxiolytic-
/antidepressive effect of galanin injected directly into the DRN is
mediated via GalR2 (Silote et al., 2013; de Souza et al., 2018).
Taken together, galanin receptors GalR1 and GalR2 play a
differential role in regulation of depression-like behavior. Thus,
galanin exerts a prodepressive effect, presumably via GalR1, while
stimulation of GalR2 has an antidepressant-like effect.
While little interest has been paid to GalR3 in relation to
mood, possibly due to its low expression in the rat (Mennicken
et al., 2002) and mouse (Lein et al., 2007) brain, a GalR3 knockout
mouse exhibits an anxiety-like phenotype (Brunner et al., 2014).
Following early studies on intra-membrane receptor-
receptor interactions (Fuxe and Agnati, 1985), receptor di-
and heteromerization have become a recognized mechanism
for signaling through GPCRs (Bouvier, 2001; Devi, 2001;
Agnati et al., 2003). Recent studies reveal that galanin receptor
heteromers exist, introducing a further degree of complexity
in interpreting galaninergic signaling in the brain (Fuxe et al.,
2012), and in relation to mood control. Thus, in addition to
GalR1 and 5-HT1A receptor heterodimers (Borroto-Escuela
et al., 2010), the galanin (1–15) fragment alone induces strong
depression- and anxiogenic-related effects and may regulate
mood via binding to GalR1 and GalR2 heterocomplexes (Millon
et al., 2014, 2017a,b). Interestingly, galanin (1-15) causes a dose-
dependent hyperpolarization of a population of hippocampal
CA3 neurons (Xu et al., 1999), and after iodination it binds to
other regions including the dorsal hippocampus, as shown in
autoradiographic studies (Hedlund et al., 1992). Taken together
these results provide evidence for a functional role of galanin
(1–15), perhaps unexpected in view of results showing a high
affinity of the N-terminal galanin (1-16) fragment to galanin
binding sites in the brain (Fisone et al., 1989).
GALANIN AND DEPRESSION-LIKE
BEHAVIOR IN RODENTS – LC
The LC and NA have since the 1960’s been a focus of clinical and
preclinical monoamine research, because of their involvement in
stress, mood control and treatment of mood disorders (Bunney
and Davis, 1965; Schildkraut, 1965; Weiss et al., 1981, 1994;
Svensson, 1987; Simson and Weiss, 1988; Page and Valentino,
1994; Schatzberg and Schildkraut, 1995; Aston-Jones et al., 1996;
Bremner et al., 1996a,b; Harro and Oreland, 2001; Charney, 2004;
Millan, 2006; Samuels and Szabadi, 2008; Seki et al., 2018).
There is a strong relationship between stress and the LC:
stress increases NA turnover, as well as tyrosine hydroxylase
activity and transcription in the LC (Korf et al., 1973; Zigmond
et al., 1974; Abercrombie and Jacobs, 1987; Komori et al., 1990;
Smith et al., 1991; Melia et al., 1992; Aston-Jones et al., 1996;
Rusnak et al., 1998; Chang et al., 2000; McDevitt et al., 2009; Ong
et al., 2014; Kawa et al., 2015). Moreover, stress activation of LC
neurons results in release of NA in the forebrain (Abercrombie
et al., 1988; Jordan et al., 1994; Vahabzadeh and Fillenz, 1994;
Ihalainen et al., 1999; Yoshitake et al., 2004) and cortical EEG
activation, i.e., arousal (Page et al., 1993). Here CRF (Vale
et al., 1981) is an important mediator of the stress-induced LC
activation (Valentino and Van Bockstaele, 2015).
Also galanin expression is upregulated in LC neurons in
response to stress/exercise (Holmes et al., 1995; Sweerts et al.,
1999; O’Neal et al., 2001; Sciolino et al., 2012; Weinshenker
and Holmes, 2016), establishing a relation between stress, NA
and galanin in LC. Similarly, a single dose of the monoamine-
depleting drug reserpine (Pletscher et al., 1955; Carlsson, 1975)
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FIGURE 7 | Time of immobility (A) and climbing (B) in the forced swim test (FST). Rats received i.c.v. infusion of aCSF, galanin (Gal), the GalR1 receptor agonist
M617, the GalR2(R3) agonist AR-M1896 or the GalR2 antagonist M871 (M871) 20 min prior to a 5 min test. Data presented as mean ± SEM. significant difference
from the control swim group; ∗one-way ANOVA, Fisher’s PLSD. Galanin, the GalR1 agonist and the GalR2 antagonist increase the immobility time versus a decrease
after the GalR2(3) agonist. From Kuteeva et al. (2008), with permission.
causes an increase in galanin mRNA levels in LC neurons
(Austin et al., 1990; Gundlach et al., 1990a). The same treatment
results in a complete depletion of galanin in the noradrenergic
cortical/hippocampal nerve terminals (Xu et al., 1998), that are
the projections of the LC neurons: evidence for the view that
release of a neuropeptide leads to increased synthesis of transcript
and peptide. NPY expression in LC has, contrasting galanin,
not been reported to be regulated by stress, but NPY mRNA is
increased after reserpine administration (Gundlach et al., 1990a).
An involvement of LC in depression-like behavior has been
studied by Weiss and colleagues focused on a link with the
ascending mesencephalic dopamine system (Weiss et al., 1981,
1996, 1998, 2005). They based their experiments on the study
by Grenhoff et al. (1993) showing that burst stimulation of
LC inhibits DA neurons in the ventral tegmental area (VTA)
(a.k.a the A10 group) (Dahlstrom and Fuxe, 1964). Weiss and
colleagues have found that infusion of galanin into the VTA
reduced exploratory behavior and increased immobility in the
Porsolt test (a.k.a. Forced Swim Test, FST), an increase that was
blocked by the galanin antagonist galantide. These findings link
the LC-galanin system to studies showing involvement of the
VTA and the reward system in stress and depression (Everitt and
Robbins, 2005; Nestler and Carlezon, 2006; Thomas et al., 2008;
Nestler, 2015; Pena et al., 2017).
The LC is involved in other mood-related behaviors such
as addiction and reward (Maldonado and Koob, 1993), and
galanin plays a role also in this context (Picciotto, 2008; Genders
et al., 2018a). Thus, galanin binding and levels of GalR1 mRNA
are increased in the LC during opiate withdrawal (Zachariou
et al., 2003). Moreover, galanin-knockout mice exhibit more
pronounced signs of opiate withdrawal, and galanin and the
galanin ligand galnon both attenuate opiate reward and signs of
withdrawal (Zachariou et al., 2003).
THE GALANIN SYSTEM IN THE NORMAL
HUMAN BRAIN
The distribution of galanin in the ‘normal’ human brain has
been studied with RIA (Bennet et al., 1991; Barde et al., 2016),
IHC (Chan-Palay, 1988a,b, 1990; Gentleman et al., 1989; Kowall
and Beal, 1989; Beal et al., 1990; Kordower and Mufson, 1990;
Kordower et al., 1992; Gabriel et al., 1994) and ISH (Miller et al.,
1999; Le Maitre et al., 2013). In addition, the receptor distribution
was analyzed with autoradiographic ligand binding methodology
(Kohler et al., 1989; Kohler and Chan-Palay, 1990). Here, recent
results obtained with ISH, qPCR and RIA on the galanin system
in the LC and some other regions are summarized (Le Maitre
et al., 2013; Barde et al., 2016). These studies were based on
the identified gene sequences of the human galanin peptide and
receptors (Evans and Shine, 1991; Jacoby et al., 1997; Lorimer
et al., 1997; Fathi et al., 1998; Kolakowski et al., 1998; Smith et al.,
1998).
In situ Hybridization
The ISH analysis of the human LC (Le Maitre et al.,
2013) revealed expression of TH, the rate-limiting enzyme
for catecholamine synthesis in presumably all noradrenergic
neurons (Figures 8A,B), galanin mRNA in many LC neurons
(Figures 8C,D) and GalR3 mRNA in many, perhaps all
neurons (Figures 8E,F), the latter two overlapping with the
TH distribution. However, whereas the levels of TH and GalR3
mRNA are relatively similar in all cells, there was a large variation
in the intensity of the galanin mRNA signal (c.f. Figures 8A,B,E,F
with Figures 8C,D). This likely reflects the fact that galanin is a
releasable molecule and that individual neurons are in different
activity states. Note that the exposure time of the emulsion dipped
slides is very different for the three markers (10 days for TH
versus several months for GalR3), reflecting differences in mRNA
levels (Figures 8A–F). Thus, GalR3 mRNA levels are very low,
in agreement with low levels in rat (Mennicken et al., 2002) and
potentially undetectable levels in mouse (Lein et al., 2007). In fact,
GalR3 transcripts could only be visualized in human brains with
very short post mortem delays prior to freezing (2–4 h).
RIA, qPCR and DNA Methylation
Barde and colleagues analyzed > 200 postmortem brain samples
from ‘normal’ (and depressed, see below) female and male
subjects, including the following regions: in addition to LC,
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FIGURE 8 | Dark-field ISH photomicrographs showing the distribution of
transcripts for tyrosine hydroxylase (TH), galanin, and GalR3 in the locus
coeruleus. The three markers TH (A,B), galanin (C,D), and GalR3 (E,F) show
overlapping distribution patterns. TH and GalR3 transcript levels seem
approximately similar in all cells. In contrast, there is variability in the strength
of the signal for galanin mRNA (white arrow points to neurons with a strong
signal, red ones to such with a weak signal). Exposure time: TH, 10 days;
galanin, 4 weeks; GalR3, 8 weeks. This difference in exposure time transcript
reflects difference in transcript levels, that is GalR3 mRNA levels are very low.
Reprinted from Le Maitre et al. (2013) [Scale bars: 200 µM for (A,C,E); 50 µM
for (B,D,F)].
dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex
(ACC), DRN and the medullary raphe nuclei (MRN)6 (Barde
et al., 2016). Three methods were applied: RIA to monitor peptide
levels, qPCR for transcript levels, and pyrosequencing to analyze
6Please note that the samples from the five regions contain a heterogeneous
collection of neurons (and of course glia), where members of the galanin family
are present to a varying percentage. (These are cell bodies, since transcripts are
monitored. However, the efficacy of probes may vary, and false negatives are not
unlikely.) The “LC” sample contains a fairly high percentage of NA neurons. In
“DRN” the 5-HT neurons probably represent a small proportion of all neurons,
also since the sample includes the vPAG, and more. In the “MRN” sample an even
smaller percentage of the neurons are serotonergic. Knowledge of the localization
of transcripts of the galanin family is available only for DRN and LC, and even here
only to a limited extent.
DNA methylation. Comparable information is presented for
ligand (galanin) (Table 1A) and transcripts (Table 1B) of galanin
and GalR1-3 in the normal (control) and (‘depressed’) male and
female brain (Barde et al., 2016).
When evaluating the results it should be noted that peptide
levels in normal brains mostly reflect peptide present in nerve
terminals and less so in cell bodies. Animal studies have shown
that galanin peptide (like many other peptides) can best be
detected in cell bodies after inhibition of axonal transport by
colchicine (Rokaeus et al., 1984; Skofitsch and Jacobowitz, 1985;
Melander et al., 1986c). In contrast, peptide transcripts are
easily seen in cell bodies/dendrites, and often confined to these
neuronal compartments.
With RIA, marked regional differences in
galanin levels were observed, being highest in DRN
( > LC > MRN > ACC = DLPFC), whereby DRN levels
were 2 times higher than in LC and ∼12 times higher than in
ACC/DLPFC. The qPCR analysis revealed the highest galanin
mRNA levels in LC (reflecting the many positive cell bodies),
about 4-fold higher than in DRN, and 6-fold higher than DLFPC,
in agreement with the ISH results (Le Maitre et al., 2013)
(Table 1A). Thus, the results from the LC suggest that there is
a good translation from mRNA to peptide. The RIA results are
generally in agreement with IHC studies on the primate brain
(Kordower et al., 1992), and on the rat brain, when analyzed with
RIA (Skofitsch and Jacobowitz, 1986) and IHC (Skofitsch and
Jacobowitz, 1985; Melander et al., 1986b; Merchenthaler et al.,
1993).
The results are also in line with the cited
immunohistochemical results in the rat with a high density
of galanin-positive nerve terminals in the DRN, and fewer in
the LC (Skofitsch and Jacobowitz, 1985; Melander et al., 1986b;
Merchenthaler et al., 1993). It is likely that galanin in cortical
areas is present in thin and rather sparse afferents to the cortex,
possibly originating in LC, as is the case in rat (Xu et al., 1998)
and also in local neurons (see below).
With regard to receptors only transcripts and methylation
were studied. This is partly due to a lack of specific antibodies
for the galanin receptors, as discussed (Lu and Bartfai, 2009;
Brunner et al., 2018), and there was no attempt to use Western
blotting, Elisa or IHC for receptors. The strongest signal by far
was noted for GalR1 mRNA, with the highest levels seen in
DLPFC ( > LC > MRN = DRN > ACC) (Table 1B). GalR1 levels
in DLFPC were 2 times higher than in LC, and the GalR1 mRNA
levels in DLFPC were 8-fold higher compared to the ‘adjacent’
ACC. GalR2 mRNA levels were in general considerably lower in
LC (64-fold lower than GalR1). The GalR3 mRNA levels were
low, although four times higher in the lower brain stem (LC,
DRN) than in cortical regions, in agreement with the ISH results
showing that GalR3 mRNA is present in NA neurons in LC, and
possibly in 5-HT neurons in the DRN (Le Maitre et al., 2013).
In summary, GalR1 mRNA is the most prominent galanin
receptor transcript in the human brain, including cortical
regions. This is in agreement with early studies on human
postmortem brain with iodinated galanin and autoradiography
that revealed a distinct cortical signal (Kohler et al., 1989; Kohler
and Chan-Palay, 1990), thus likely representing GalR1. The
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TABLE 1 | (A,B) Concentration of galanin peptide (pmol/mg ± SEM) analyzed by RIA (A) and raw Ct values ± SEM monitored by qPCR (B) for male and female control
and suicide samples from five brain regions.
DLPFC ACC DRN LC MRN
(A) Region
Male Con 3.9 ± 1.2 5.4 ± 1.2 61.6 ± 13.7 31.8 ± 7.5 15.6 ± 2.3
Male DS 2.7 ± 0.5 4.9 ± 1.0 68.1 ± 11.6 37.4 ± 10.7 18.7 ± 4.8
Female Con 1.7 ± 0.4 6.4 ± 1.8 80.6 ± 10.2 43.4 ± 6.3 15.5 ± 3.5
Female DS 1.3 ± 0.3 6.0 ± 1.3 81.6 ± 5.2 67.7 ± 7.5 13.5 ± 2.9
(B) Region
Galanin 27.1 ± 0.2 27.5 ± 0.1 26.2 ± 0.4 24.6 ± 0.5 25.2 ± 0.4
GalR1 25.7 ± 0.2 28.6 ± 0.1 27.0 ± 0.4 26.4 ± 0.6 26.9 ± 0.4
GalR2 31.4 ± 0.2 31.6 ± 0.2 29.3 ± 0.2 32.3 ± 0.1 34.6 ± 0.2
GalR3 33.2 ± 0.1 33.5 ± 0.2 31.5 ± 0.4 31.4 ± 0.6 31.9 ± 0.4
From Barde et al. (2016). Con, controls, DS, depressed suicides; DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; DRN, dorsal raphe nucleus;
LC, locus coeruleus; MRN, medullary raphe nuclei; Gal, galanin. Italics indicate significantly lower galanin levels in male vs. female depressed suicides.
results differ from rat, since the early ligand binding studies
in adult rat lacked binding in dorsal cortical areas (Skofitsch
et al., 1986; Melander et al., 1988), and since GalR1 and -R2
mRNA levels are low (O’Donnell et al., 1999; Burazin et al., 2000).
Thus, cortical receptor levels may represent another species
difference not only between rat and human, but also between rat
and mouse (Jungnickel and Gundlach, 2005). However, overall,
GalR1 is also the most prominent galanin receptor in the rat
brain (O’Donnell et al., 1999; Burazin et al., 2000) and likely
also in mouse brain (Hohmann et al., 2003; Jungnickel and
Gundlach, 2005; Lein et al., 2007). Waters and Krause (2000)
monitored the levels of transcript for all three galanin receptors
in the rat brain: GalR1 is highest in amygdala and spinal cord,
whereas in cortex GalR2 > GalR1 > GalR3, and in hippocampus
GalR2 > GalR1 = GalR3. In that study values were expressed as
mean pg/25 µg total RNA.
The interpretation of the human qPCR results is not straight
forward. For example, there is a lack of knowledge of the cellular
localization of the transcripts in the prefrontal cortex regions, i.e.,
these areas have not been studied with ISH. It is likely that the
transcripts are present in neurons, but a glial localization cannot
be excluded (Butzkueven and Gundlach, 2010). Under certain
circumstances galanin is expressed in specialized glial cells, e.g.,
after colchicine treatment alone or after spreading depression (Xu
et al., 1992; Shen et al., 2003, 2005). The colchicine-induced signal
was abolished by thyroidectomy (Calza et al., 1998). However,
the results strongly suggest that galanin, and possibly all three
galanin receptors, or at least GalR1, are expressed locally in cells,
likely in cortical neurons. In contrast, ISH results are available
for DRN and LC and reveal neuronal localization (Le Maitre
et al., 2013). In particular, the results on the LC offer a possibility
to form a hypothesis about the galanin system in this nucleus
being involved in stress and genesis of depression, as discussed
below.
Overall major differences exist between species, both with
regard to galanin and galanin receptor expression, whereby
galanin signaling seems to be more important for dorsal cortical
functions in the human brain than in rodents. In contrast, in the
rat ventral cortical areas, like entorhinal and piriform cortices,
have abundant galanin receptor expression (Skofitsch et al., 1986;
Melander et al., 1988; O’Donnell et al., 1999; Burazin et al., 2000),
suggesting involvement in limbic processes.
DEPRESSIVE DISORDERS
Major depressive disorder (MDD) is a common and serious
disease aﬄicting up to 2–5% (12-month prevalence; lifetime
prevalence 10–15%) of the population worldwide, and women
being more susceptible than men. Thus, MDD is a leading
cause of disability worldwide associated with much suffering
and major costs for society (Murray and Lopez, 1997; Kessler
et al., 2003; Wittchen et al., 2011; Ferrari et al., 2013; World
Health Organization [WHO], 2013). Adverse life events usually
precede depression episodes, and experiences of physical and
emotional abuse during early childhood and parental neglect are
important predisposing vulnerability factors, strongly indicating
that environmental psychosocial stressors are essential in
pathogenesis (Kendler, 2012, 2013; Lutz et al., 2017; Tanti et al.,
2017). The heritability is significant, about 35% (Sullivan et al.,
2000). Interaction of genetic and environmental factors including
stressful life events plays a major role in the development of MDD
(Nestler et al., 2002; Akil, 2005; de Kloet et al., 2005; McEwen,
2007; McEwen et al., 2015). Epigenetic mechanisms through
altered DNA methylation (Meaney and Ferguson-Smith, 2010;
Zhang and Meaney, 2010) are probably involved, leading to stable
changes in brain function that may underlie the psychopathology
(Labonte et al., 2013; Vialou et al., 2013).
Over the last several decades two major hypotheses of
the cause of unipolar depression have dominated, clinically
associated with catecholamines (Bunney and Davis, 1965;
Schildkraut, 1965; Schatzberg and Schildkraut, 1995) and
with serotonin (Coppen, 1968; Maes and Meltzer, 1995).
Pharmacological management of depression therefore often
involves drugs that target the monoamine transporters, which
include SSRIs, the transporter for noradrenaline (NA) (NRIs) or a
combination of both (SNRIs) (Gardier et al., 1996; Mongeau et al.,
1997; Millan, 2006), as well as a number of other medications
(Berton and Nestler, 2006; Millan et al., 2015b). However, the
therapeutic efficacy of these antidepressants is hampered by a
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slow onset of action, a limited response rate and considerable side
effects (Montgomery, 2006; Trivedi et al., 2006). Of particular
importance is the treatment resistant depression which affects
some 20% of aﬄicted subjects (Akil et al., 2018). These issues have
led to an intensive search for novel therapeutic approaches for
MDD (Berton and Nestler, 2006; Artigas, 2015; Akil et al., 2018)
(and see below), including targeting receptors for neuropeptides
(Maubach et al., 1999; Hokfelt et al., 2003; Holmes et al., 2003;
Nemeroff and Vale, 2005; Griebel and Holsboer, 2012), the most
diverse family of brain messenger molecules (Burbach, 2010).
THE GALANIN SYSTEM AND
DEPRESSION IN HUMANS
The evidence from animal experiments described led us to
explore to what extent galanin may be involved in MDD and
other mood disorders, and whether results from the analysis of
human brain can guide the search for new antidepressants.
Genetic Variations in the Galanin System
in Depression
A candidate gene study of a cohort of European White ethnic
origin totaling 2,361 from Manchester, United Kingdom and
Budapest, Hungary was carried out (Juhasz et al., 2014) and
revealed that variants in genes for galanin and its three receptors
confer increased risk of depression and anxiety in people who
experienced childhood adversity and/or recent negative life
events (Figure 9). Genetic factors were only relevant in the
moderate or high stress exposure groups when applying Bayesian
multivariate analysis (Juhasz et al., 2014; Gonda et al., 2018).
The rank order of the relevance of gene polymorphisms was
GalR2 > GalR3 > GalR1 > galanin, with strong relevance for
the first three in the moderately or highly exposed persons
by recent negative life events in the last 12 months. All four
were more relevant than the serotonin transporter gene-linked
polymorphic region (5-HTTLPR) of the serotonin transporter
gene. The effects were seen in the Manchester and the Budapest
population, and in both males and females. This impact was
seen only if taking stress into account, after medium and strong
stress (the GalR2 gene) or strong stress (the GalR3, GalR2 and
galanin genes), underlining the importance of environmental
factors. In addition, the GalR2 gene polymorphism was more
relevant than candidate gene polymorphisms of the genes for
BDNF, the serotonin 1A receptor (HTR1A), the cannabinoid 1
receptor (CB1) and the serotonin 2A receptor (HTR2A) in the
moderately stress exposed subjects (Gonda et al., 2018). The
traditional analysis based on general linear models confirmed the
gene-environment interaction; namely, no main effect of genes,
but a significant modulatory effect of environment-induced
development of depression were found.
Evidence for collaboration between small neurotransmitter and
neuropeptide in the development of depression was also identified
in this study, namely a gene–gene–environment interaction
between the GalR2 and 5-HTTLPR genes in strongly exposed
persons (Gonda et al., 2018). This could be of interest regarding
antidepressant drug targets. The expression of the GALR2
FIGURE 9 | Galanin mechanisms hypothetically involved in MDD in humans.
Galanin and its receptors are colocalized in some monoaminergic neurons in
the brain. The galanin system is highly sensitive to experimental and
naturalistic stressors. Stress-induced activation of the galanin system
represents the first phase in the development of depression. Recent analysis
of human brain has shown that the Gi protein-coupled GalR3 (and not GalR1
as in rodents) is the main galanin receptor in noradrenergic neurons in the
locus coeruleus and probably the dorsal raphe nucleus and that the Gi
protein-coupled GalR1 is the main receptor in the forebrain. Antidepressive
effects may be achieved by (i) GalR3 antagonists, by reinstating normal
monoamine turnover in LC neurons in the lower brainstem projecting to the
forebrain, and by (ii) GalR1 antagonists in the forebrain by normalization of
limbic system activity, or by (iii) agonists at GalR2, a Gq protein-coupled
receptor, promoting neuroprotection. A candidate gene analysis suggests that
GalR1 risk variants may compromise galanin signaling during childhood,
whereas GalR2 signaling may be influenced by recent negative life events. In
addition, all four galanin system genes have relevant roles in the development
of depression-related phenotypes in those persons who were highly exposed
to life stressors. From Juhasz et al. (2014).
polymorphism is about 2.5 times higher compared to 5-HTTLPR.
Currently, the most frequently used antidepressants are the SSRIs,
NRIs and SNRIs. Preliminary pre-clinical results suggest that an
SNRI (venlafaxine) does not alter the transcript levels of galanin
and its receptors (Petschner et al., 2016). Other studies show that
chronic treatment with SSRIs increases galanin mRNA levels in
various brain regions (Christiansen et al., 2011; Rovin et al., 2012;
Yamada et al., 2013). The higher relevance of the GalR2, GalR3
and GalR1 gene polymorphisms in stress-induced depression
and the galanin system-independent effects of the currently
used antidepressants suggest that novel antidepressants acting
on GalR1-3 could be developed. Such compounds could perhaps
be more effective in SSRI/SNRI non-responders.
Galanin Versus 5-HT Transporter in
Depression
For a long time, it has been assumed that there is an interaction
between stressful life events and a polymorphism in the promoter
region of the 5-HT transporter (5-HTT) gene (SLCA4) (Lesch
et al., 1996; Caspi et al., 2003). In the Newmood cohort this
effect was weak and not significant in most comparisons, when
corrections for multiple testing were applied (Juhasz et al., 2015).
Furthermore, Bayesian relevance analyses consistently failed to
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show relevance for 5-HTTLPR (Juhasz et al., 2014; Gonda et al.,
2018). Parallel to these findings, a recent large meta-analysis
could not confirm an interaction (Culverhouse et al., 2018). The
findings on the galanin system provide evidence for a more
robust and relevant effect of galanin system genes compared to
5-HTTLPR of the serotonin transporter gene (Juhasz et al., 2014;
Gonda et al., 2018). The 5-HTT and GalR2 receptor act jointly in
the development of depression (Gonda et al., 2018).
Other Genetic Studies
Involvement of galanin in depression is further supported by
a gender-specific association of galanin polymorphisms with
antidepressant treatment response (Unschuld et al., 2010) and
by a study reporting an association of galanin and MDD in
the Chinese Han population (Wang et al., 2013). In addition,
the first large genome-wide association study (GWAS) obtained
a suggestive association of GAL with MDD using a gene
based test, which retained low association p-values in two
additional independent cohorts (Wray et al., 2012). A very
large GWAS failed to identify risk genes (Major Depressive
Disorder Working Group of the Psychiatric Gwas Consortium,
2013), but recent advances in large MDD GWAS studies
resulted in several SNPs being associated with MDD (e.g.,
Hyde et al., 2016; Okbay et al., 2016; Xiao et al., 2017;
Wray et al., 2018), and provided further evidence that genetic
risk for depression is a continuous measure that translate
environmental adversities into depressive symptoms. Taken
together, the genetic analysis of the four members of the galanin
system genes are complemented by a study on postmortem
brains from depressed suicides (Barde et al., 2016), strengthening
an involvement of galaninergic mechanisms in depression, as
discussed below.
Multiple Changes in the Galanin System
in MDD
Differences in levels of galanin peptide, and of transcripts for,
and DNA methylation of, galanin and GalR1-3 between MDD
patients and matched controls were observed in an analysis
of > 200 postmortem samples from five male and female brain
regions (DLPFC, ACC, DRN, LC, and MRN). The significant
and selective differences and changes in the galanin system in
depressed versus control brains are summarized in Table 2. The
most pronounced changes were observed for galanin and GalR3
in the DLPFC, and for galanin and GalR3 in the DRN and LC,
in males and females (examples of results in Figures 10A,B).
In DRN and LC there was an upregulation of the transcripts,
paralleled by a decrease in DNA methylation. The decrease in
methylation in galanin and GalR3 was most pronounced in
female DRN and in male and female LC. In DLPFC, galanin
mRNA levels were decreased in males and increased in females,
the only distinct sex difference observed in the study. The changes
in GalR1 were also increased and confined to three regions,
DLPFC (male and female), DRN (male) and MRN (male), versus
no change in LC. No differences were seen with regard to
GalR2, except a decrease in MRN, included as a control region.
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FIGURE 10 | (A,B) Alterations in galanin (A) and GalR3 (B) gene expression and DNA methylation in the locus coeruleus (LC) of male and female depressed
subjects who committed suicide, as compared to matched controls. (a,e) Expression levels of the two genes in the LC of male (a) and female (e) controls and
depressed suicide (DS) subjects. (b–d,f–h) Percentage of DNA methylation levels at individual CpG sites of the two genes in male (b–d) and female (f–h) controls
and DS subjects. All data are presented as mean ± SEM; males: n = 10 controls, 10 DS subjects; females: n = 12 controls, 10 DS subjects. Significant differences
between DS subjects and controls are indicated: ∗P < 0.05, ∗∗P < 0.01. CON, controls. From Barde et al. (2016).
alterations in DLPFC, both regions belonging to the prefrontal
cortex complex.
With regard to methylation, changes were always opposite to
those in transcript levels. This is in agreement with the general
view that methylation suppresses transcript synthesis (Moore
et al., 2013). The results lend further support for an involvement
of epigenetic mechanisms in MDD (Mill and Petronis, 2007;
Machado-Vieira et al., 2011; Vialou et al., 2013; Lolak et al., 2014;
Lopizzo et al., 2015; Saavedra et al., 2016; Hoffmann et al., 2017;
Nagy et al., 2018).
Taken together, the results suggest that galaninergic
mechanisms, in several brain regions, are involved in MDD, and
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that epigenetic changes mediated by DNA methylation play an
important role, in agreement with a candidate gene study (Juhasz
et al., 2014).
INVOLVEMENT OF GALANIN IN
DEPRESSION AND RESILIENCE – A
HYPOTHESIS
The LC in humans is a compact (but less so than in rodents),
‘blue’ (pigmented) nucleus consisting of a total (both sides) of
around 50,000 neurons (German et al., 1988; Baker et al., 1989;
Chan-Palay and Asan, 1989; Miller et al., 1999; Szot et al., 2000).
As in other mammalian species studied, galanin is expressed in
a large proportion of the human noradrenergic neurons (Chan-
Palay et al., 1990; Kordower et al., 1992; Miller et al., 1999; Le
Maitre et al., 2013), suggesting conservation during evolution.
However, there are differences with regard to receptors. Thus
the GalR3 receptor seems to be the most prominent receptor in
the LC, contrasting the robust expression of GalR1 and GalR2 in
the rat LC (O’Donnell et al., 1999; Burazin et al., 2000). Neither
GalR1 nor -R2 mRNA was, surprisingly, detected with ISH in
human NA neurons, although a GalR1 signal was seen in the
LC region and in other regions, suggesting that the probe was
functional. However, it cannot be excluded the NA LC neurons
contain lower levels of GalR1 than other types of neurons and
thus escaped detection. Thus, a distinct species difference seems
to exist. Another apparent species difference was the possible lack
of galanin expression in the human 5-HT neurons (Le Maitre
et al., 2013), as is the case also in the mouse (Larm et al., 2003;
Kuteeva et al., 2004; Lein et al., 2007; Fu et al., 2010), versus a
robust expression of galanin in rat 5-HT neurons (Melander et al.,
1986c; Fuxe et al., 1990; Priestley et al., 1993; Xu and Hokfelt,
1997).
How and when neuropeptides and classic transmitters
are released has been explored (see Lundberg and Hokfelt,
1983; Hokfelt, 1991; Lundberg, 1996). Neuropeptides, stored
in LDCVs, are mainly released when neurons are firing at a
high rate or in bursts, e.g., during stress. This release occurs
extrasynaptically, and not only from nerve endings but also from
soma/dendrites. Merging this information and the results from
MDD patients (Barde et al., 2016) it is possible to generate a
hypothesis how depression in humans, likely a (stress-related)
subtype of MDD, may develop (Figure 11): Under normal
circumstances LC neurons fire at low frequencies, releasing NA in
cortical regions, acting on post- and pre-synaptic adrenoceptors.
Under stress, when LC neurons fire in bursts, also galanin
will be released, together with NA, from nerve endings and
soma/dendrites of the NA LC neurons, galanin acting on
somatic/dendritic GalR3 autoreceptors.
GalR3 is, like GalR1, inhibitory (Smith et al., 1998) and causes
hyperpolarization of the LC neurons, the purpose being to act as
a ‘brake’ to prevent overexcitation, to keep the system in balance.
This is similar to the proposed function of the 5-HT1A receptor
as a “safety valve” of 5-HT neurons (Celada et al., 2013). As a
consequence of increased firing and increased galanin release,
synthesis of new peptide is initiated, reflected in increased mRNA
levels. The fact that in dendrites sites of synthesis and release are
close allows for rapid replacement. Thus, if mRNA is translated,
increased galanin levels will be available for release from soma
and dendrites, a feed-forward process. The additional increase
in GalR3 transcript, presumably resulting in increased levels
of receptor protein, could represent a robust increase in local
galanin signaling. This seems unexpected, because intuitively one
would expect downregulation of the receptor, following elevated
levels of ligand. However, the inhibition may be strong and
long-lasting leading to depletion of NA in the forebrain. The
results suggest that mood disorders may be a consequence of a
maladaption, an allostatic load (McEwen, 2003).
It may be emphasized that the prefrontal cortex has not
been included in the discussion, even if significant changes in
levels of galanin transcripts and methylation were recorded in
this region of depressed subjects (Barde et al., 2016). This is
because lack of knowledge about the cellular localization of the
galanin system in this brain area. Finally, a similar scenario
for an anti-depressive role of a GalR3 antagonist could be
sketched for the 5-HT neurons in the DRN, since the galanin and
GalR3 transcripts are upregulated both in the male and female
DRN region from depressed patients who committed suicide,
paralleled by decreased DNA methylation of the GalR3 gene in
the female depressed subjects (Barde et al., 2016).
Of note, in the Barde et al. (2016) study the end
stage of a mostly long development of the disorder is
recorded, where all ‘resources’ have been mobilized to prevent
overexcitation: increased ligand release plus increased receptor
availability. Alternatively, the situation may reflect changes
beyond patho-physiological regulatory mechanisms, especially
when considering the considerable time it takes for depression
to arise7.
Resilience
Even if many humans are exposed to stress of various types
and intensity, only comparatively few develop depression, thus
displaying resilience to stress (Nestler et al., 2002; Southwick
et al., 2005; Han and Nestler, 2017). Resilience appears to
represent an active process involving several systems, including
not only the mesolimbic dopamine neurons (Han and Nestler,
2017) but also other systems, such as the noradrenergic
LC neurons (Charney, 2004; Feder et al., 2009; Krystal and
Neumeister, 2009; Sciolino et al., 2015; Valentino and Van
Bockstaele, 2015; Isingrini et al., 2016). Specific molecules,
e.g., BDNF and neuropeptides like opioids and CRF, have also
been implicated (Russo et al., 2012). Of particular interest in
the present context is NPY (Kask et al., 2002; Morgan et al.,
2002; Heilig, 2004; Krishnan et al., 2007; Zhou et al., 2008;
Domschke et al., 2010; Cohen et al., 2012; Sabban et al., 2016;
Kautz et al., 2017), a neuropeptide discovered in the Mutt
laboratory (Tatemoto et al., 1982). NPY may be involved in the
7In the early electrophysiological in vitro experiments on rat LC neurons in slices, a
marked and lasting (20 min) desensitization developed after application of galanin
(Pieribone et al., 1995). If this is true also for GalR3 in the human LC is not known;
nor how such an effect, if present, would contribute to/would be of importance for
the results obtained in our study on depressed suicides (Barde et al., 2016), and for
the present hypothesis.
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FIGURE 11 | The galanin–locus coeruleus (LC) system in stress and depression: A hypothesis. The hypothesis is built on animal (rat) experiments showing that (i)
galanin and GalR1 (top left) are present in LC NA neurons; (ii) galanin mRNA levels are increased during stress; (iii) galanin via GalR1 autoreceptors inhibits firing of
LC neurons; and (iv) indirect evidence that galanin can be released from soma-dendrites of LC neurons. The second corner stone is results from two studies on
human postmortem brain with ISH and qPCR. Five regions from postmortem brains from depressed subjects who committed suicide and controls were studied and
are shown, including LC that projects to anterior cingulate and dorsolateral prefrontal cortices (top right). The results show that also in humans (i) the NA LC
neurons express in any case galanin and GalR3 (top left). GalR1 and GalR3 probably have similar transduction mechanisms (top left). Under ‘normal’ firing only
noradrenaline is released in forebrain. A situation after severe stress is depicted in the lower panel: LC neurons burst fire (lower panel, middle), NA and galanin are
released from nerve endings in cortex (lower panel, left) and dendrites in the LC (lower panel, right), the latter in an attempt to prevent overexcitation (a resilience
mechanism). To replace released peptide, galanin transcript levels and synthesis increase, and also GalR3 is upregulated (lower panel, right). The increased release,
together with elevated galanin and GalR3 levels, result in a too strong inhibition and decreased NA levels in the forebrain (maladaptation) (lower panel, left), possibly
contributing to depressive symptoms. HiFo, hippocampal formation. Drawing by Mattias Karlén.
control of LC signaling in a similar way as galanin, but this
will not be discussed further here, because limited information
is available on the expression of NPY and NPY receptors
in the brain of normal subjects and subjects who committed
suicide.
The present data suggest that the GalR3-mediated ‘brake’
on the LC neurons is part of the resilience ‘machinery’ in
humans. This is in agreement with animal experiments on rats
by Sciolino et al. (2015) who show that exercise increases galanin
levels in LC, and that exposure to stress reduces open arm
exploration in sedentary rats. But this effect is not seen in exercise
rats – and not in rats treated chronically with galanin given
intraventricularly (i.c.v.); and it could be blocked by chronic
administration of the galanin antagonist M40. Thus, increased
galanin levels, presumably in LC, promotes resilience. This is
also suggested by earlier animal experiments, as summarized by
Sciolino et al. (2015): i.c.v. galanin protects against anxiety under
stressful conditions (Bing et al., 1993), but not in the absence
of stress (e.g. Holmes et al., 2005); i.c.v. M40 blocks fluoxetine-
induced activity in the FST (Lu et al., 2005a); and transgenic
mice overexpressing galanin under the dopamine B-hydroxylase
promoter (the GalOE/D mouse), i.a. in LC, are protected against
stress (Holmes et al., 2002).
The resilience hypothesis is further supported by comparison
of the GalOE/D mouse (Steiner et al., 2001) with a mouse
overexpressing galanin under the platelet growth factor B
(PDGFB) promoter (the GalOE/P mouse) (Holmberg et al.,
2005). Analyzing the effect of swim stress with microdialysis, it
was shown that NA release in the forebrain is much lower in the
GalOE/D than in the GalOE/P mouse (Yoshitake et al., 2004). The
histochemical/qPCR analyses revealed that the galanin mRNA
levels in the LC are 5 times higher in the GalOE/D than in
wild type mice (Steiner et al., 2001). On the other hand, the
GalOE/P mouse has a lower galanin expression in the LC and in
(noradrenergic) nerve terminals in the forebrain (Kuteeva et al.,
2004; Yoshitake et al., 2004). One possible explanation is that
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the higher galanin levels in the GalOE/D mouse suppress NA
release in the forebrain by autoinhibition of the LC neurons, in
agreement with the hypothesis.
The behavioral analyses of these two mouse lines reveal that
the GalOE/P mouse displays an increased time of immobility
in the FST, that is a depression-like behavior (Kuteeva et al.,
2005). In contrast, there are no differences in immobility
time on tail suspension between GalOE/D and wild type mice
(Holmes et al., 2005). One interpretation is that the GalOE/D
mouse is resilient to stress thanks to increased inhibitory
galanin signaling in the LC, again, in agreement with the
hypothesis.
DRUG TREATMENT VIA NEUROPEPTIDE
RECEPTORS
The fact that neuropeptides routinely signal via GPCRs is
promising from the perspective of drug development, since
>30% of all prescription drugs act via such receptors (Luttrell
et al., 2015; Hauser et al., 2017; Santos et al., 2017). Thus, >200
neuropeptide receptors are potential drug targets.
Principles for Peptidergic Co-signaling
Peptide signaling in the rodent, and possibly primate, brain
likely always means co-transmission with one or more small
molecule transmitters – and other peptides. How could this
affect treatment of patients? Are there any problems, or even
advantages? Here some thoughts.
To fully block signaling at least two antagonists may be
required. For example, a substance P antagonist is potentially
a pain killer, since this excitatory peptide is released from
nociceptors. However, the clinical tests failed for the reasons
discussed (Hill, 2000; Herbert and Holzer, 2002). An obvious
explanation would be that at least two additional excitatory
transmitters are co-released with substance P from the same
nerve endings in the dorsal horn: glutamate and CGRP, which are
co-stored together with substance P in the same LDCVs (Merighi,
2002) (Figure 1E). So, blockade of one (the NK1) receptor may
not be sufficient to achieve analgesia.
There could be advantages with peptide transmitters: First,
neuropeptides are ’weak’ messengers. Thus, an antagonist will not
have the potentially detrimental effects of blocking ‘strong’ and
functionally essential fast transmitters, like those for GABA and
glutamate. Although glutamate antagonists have many obvious
indications for treating disease, it has been difficult to develop
clinically efficacious and safe medicines. For example, glutamate
is the major transmitter in nociceptors, and glutamate ligands
have been strong candidates for pain treatment (Neugebauer,
2007), but glutamate antagonists like ketamine have yet to emerge
as a clinically safe and widely used treatment alternative for pain
(Bell et al., 2017). This said, and important in the context of
the present review (MDD), the introduction of ketamine and
ketamine analogs causing rapid antidepressant effects in subjects
with treatment resistant depression has been, to say the least, an
exciting advance (Zarate et al., 2006; Abdallah et al., 2015; Lener
et al., 2017).
Furthermore, if neuropeptides are only released when neurons
are firing at high frequency or firing in bursts, then antagonists
would only have an effect under these circumstances, that is only
affecting an activated system. For example, galanin is present
in >20 nuclei in the rat brain. However, stress may primarily
activate LC and 5-HT neurons, which in rats may be the only
neurons releasing galanin. And an antagonist will consequently
antagonize only the effects of galanin released from these two
systems. The remaining galanin systems are silent and will
therefore not be affected by the antagonist – so likely only few
side effects. In contrast, a NA reuptake inhibitor will affect all
NA neurons, resulting in increased extracellular amine levels in
virtually all brain regions, probably leading to side effects. The
same is of course true for SSRIs and serotonin, as well as for
SNRIs and serotonin plus NA.
Treatments via Peptidergic Mechanisms
Are Effective
The discovery by the pharmaceutical company Merck of small
non-peptide molecules passing the blood-brain-barrier (Uslaner
et al., 2013) and acting as antagonists at orexin/hypocretin
receptors (de Lecea et al., 1998; Sakurai et al., 1998) has
resulted in a new medicine: Suvorex/Belsomra, approved by the
federal drug administration (US FDA) for treatment of insomnia
(Coleman et al., 2012; Yang, 2014): in less than 20 years from
bench to patient! The small molecule co-transmitter in these
orexin/hypocretin neurons is glutamate (Rosin et al., 2003),
and these neurons also express the opioid peptide dynorphin
(Chou et al., 2001). Furthermore, monoclonal antibodies8 to
calcitonin gene-related peptide (CGRP) (Aimovig, erenumab),
a peptide also present in nociceptors (Rosenfeld et al., 1983),
are now approved by FDA and EMA for treatment of migraine
(Silberstein et al., 2017; Edvinsson et al., 2018). In fact, antibodies
to the CGRP receptor and CGRP antagonists are also efficacious
in treatment of migraine (Silberstein et al., 2017; Edvinsson
et al., 2018). Here some 35 years passed from the discovery
to the clinic. Moreover, the NK1 antagonist (Aprepitant)
mentioned in relation to depression is now used for treatment
of chemotherapy-induced emesis (Pendergrass et al., 2004), a
serendipitous finding
Drugs Acting on Galaninergic Signaling
It has been difficult to generate small molecules that pass
the blood-brain-barrier and act on central galanin receptors.
Bartfai and associates made significant contributions, starting
with chimeric peptide ligands (Bartfai et al., 1992). For
several years, these were important tools in the galanin field,
although they did not penetrate into the brain/spinal cord
from the periphery. GalR3 antagonists (SNAP 39899 and related
compounds) were then the first molecule acting on the brain
after peripheral administration (Swanson et al., 2005; Barr et al.,
2006; Konkel et al., 2006a,b). An allosteric modulator, a GalR2
agonist passing the blood-brain-barrier, was also reported (Lu
8Monoclonal antibodies were ‘invented’ more than 40 years ago (Kohler and
Milstein, 1975; Milstein, 1990), and have during the last decades become
indispensable tools for treatment of an array of diseases.
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et al., 2010), followed by further GalR2 ligands (Saar et al.,
2013a,b). Several overviews of the field have been published
(Mitsukawa et al., 2008; Hoyer and Bartfai, 2012; Webling et al.,
2012; Freimann et al., 2015).
Based on the discussion above it appears that a GalR3
antagonist is a promising candidate for treatment of depression.
Experiments in rats, suggest that the GalR1 receptor in LC also
is a target for treatment of addiction (Picciotto, 2008; Genders
et al., 2018a). However, in humans the correct receptor may
be GalR3. In fact, in two genetic studies on alcoholism, both
the galanin gene (Belfer et al., 2006) and, interestingly, the
GalR3 gene, but not the other two receptor genes, have been
implicated (Belfer et al., 2007). Of note, a GalR3 knockout
mouse exhibits an alcohol-preferring phenotype (Genders et al.,
2018b).
Why would a GalR3 antagonist be an advantageous choice
over reuptake blockers? Analysis of regions of the postmortem
MDD brains and controls (Table 1) reveals upregulation of
galanin and GalR3 not only in the LC but also in the DRN
(Barde et al., 2016). These changes are likely associated with
higher levels of released galanin and of available receptors.
Thus, a GalR3 antagonist could disinhibit blockade of two
monoamine systems critical in mood disorders and restore
both NA and 5-HT forebrain levels, relieving depressed mood.
Since no changes are seen in the ACC, and since galanin and
GalR3 are downregulated in the male DLPFC, these systems
are likely ‘silent’. Thus, treatment with a GalR3 antagonist




The key message of the present review is that the neuropeptide
galanin and its subtype 3 (GalR3), both coexisting in
noradrenergic LC neurons, are involved in MDD as part of
the resilience machinery and GalR3 as a target for treatment.
The hypothesis is based on solid and reproduced animal
experiments from several laboratories. However, the translation
to humans represents a major ‘jump,’ only involving one single
(large) experiment on postmortem brains and a supporting
candidate gene study. Thus, the hypothesis needs confirmation,
preferably by other laboratories and methods. GWAS reports
are negative, and no support based on imaging is published.
A key experiment would be to label a GalR3 antagonist and
carry out both in vitro autoradiography and positron emission
tomography to analyze GalR3 binding sites/receptors. Moreover,
the results are mainly based on transcript analysis, and it will
be necessary to show translation into receptor protein, both
in the rodent and human brain. The final proof would be to
test a GalR3 antagonist in the clinical setting, but that would
require generation of new, non-toxic molecules. Therefore,
the retraction of major pharmaceutical companies from
the neuroscience field represents a major disappointment.
Further aspects on ‘limitations’ can be found in Barde et al.
(2016).
CONCLUDING REMARKS
The discovery of new drugs for treatment of mental illness
has often been the result of serendipity (Celada et al., 2013;
Millan et al., 2015a). The present review suggests that results
from experimental animal studies can generate hypotheses that
can be further validated by examining postmortem brains from
relevant patient groups, perhaps leading to new pharmacological
treatment strategies.
In animal studies the neuropeptide galanin has shown
consistent changes in expression in response to a variety of
stimuli, including stress. In agreement, results on the four
galanin system genes (Juhasz et al., 2014), together with a
recent study conducted with postmortem brains from depressed
suicides (Barde et al., 2016), suggest involvement of galaninergic
mechanisms in depression. On the basis of these studies,
it is hypothesized that galanin may, via inhibitory GalR3
autoreceptors, act as a ‘brake’ to prevent overexcitation of
LC neurons, representing a resilience mechanism to protect
against depression. Galanin is, however, only one factor
in a comprehensive network of built-in safeguards against
overexcitation of LC neurons, reflecting the functional
importance of a strict control of noradrenergic LC neurons
which project to virtually all parts of the central nervous system.
It is now some 45 years since fluoxetine was generated,
and 35 years since the first monoamine (serotonin)-reuptake
inhibitor (Zimelidine) was launched (Spector et al., 2018). Since
then SSRIs, NRIs and SNRIs have been the most widely used
drugs for treatment of depression. Here we speculate that an
antagonist at GalR3 receptors in noradrenergic LC neurons could
lead to enhanced NA release in the forebrain – and recovery
from disease. Since GalR3 is also likely present and upregulated
in 5-HT neurons, it is possible that the same GalR3 antagonist
also could normalize 5-HT release in the forebrain as well.
Such a GalR3 antagonist has been developed (Swanson et al.,
2005). However, the GalR3 antagonist SNAP 37889 has shown
in vitro toxicity (Koller et al., 2016), and clinical trials have been
terminated due to safety concerns.
If a GalR3 antagonist without toxic side effects will be
developed and if ever tested in the clinic, the question might
arise: Why would this drug be an advantage over a combined
reuptake inhibitor, like Venlafaxine? Since the GalR3 antagonist
works by a different mechanism it may, hypothetically, avoid
some of the well-known side effects of reuptake inhibitors by a
restricted site of action, versus the reuptake inhibitors increasing
monoamine levels at all sites in the brain. It may be further
speculated that the well-known delay of onset may be avoided,
since the postulated disinhibition of the NA and 5-HT neurons
via GalR3 antagonism should be a fast effect, perhaps without
the complex ‘compensatory’ changes occurring after treatment
with SSRIs and related to the 5-HT1A receptors (Celada et al.,
2013). A third consideration is the consistently higher relevance
of GalR3 gene variants compared to those of the serotonin
transporter in stress-related depression, which might serve as
a basis of personalized treatment. To what extent treatment
resistant subjects will be helped is another issue that needs
to be addressed. Finally, the use of agents acting at multiple
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sites, e.g., blocking monoamine re-uptake plus the NK1 receptor,
may represent a way forward (Millan, 2009). In this respect,
perhaps a drug combining blockade of a galanin receptor
with another receptor/mechanism could represent an interesting
alternative?
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